<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1310222732
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1998
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MIRENA 52 MG INTRAUTERINE DELIVERY SYSTEM (IUS)
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVONORGESTREL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        52
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Vaginal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Intrauterine delivery system
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Box
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        379.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER OY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER OY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 587]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            EBRAHIM M. ALMANA & BROS. CO.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER OY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Mirena is and what it is used for</p><p>&nbsp;</p><p>Mirena is a T-shaped intrauterine delivery system (IUS) which after insertion releases the hormone levonorgestrel into the womb. The purpose of the T-body is to adjust the system to the shape of the womb. The white vertical arm of the T-body carries a drug reservoir containing levonorgestrel. Two brown removal threads are tied to the loop at the lower end of the vertical arm.</p><p>&nbsp;</p><p>Mirena is used for prevention of pregnancy, heavy menstrual bleeding, menstrual pain, and as progestogen treatment during menopausal hormone replacement therapy.</p><p>&nbsp;</p><p>Mirena contains levonorgestrel which can sometimes be used in the treatment of illnesses other than the ones mentioned in this leaflet. Ask your doctor, pharmacist or other healthcare professional for advice, if necessary, and always follow their instructions.</p><p>&nbsp;</p><p><em>Children and adolescents</em></p><p>Mirena is not intended for use before the first menstrual bleeding.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What you need to know before you use Mirena</p><p>&nbsp;</p><p><strong>General notes</strong></p><p>Before you can begin using Mirena, your doctor will ask you some questions about your personal health history and that of your close relatives.</p><p><strong>&nbsp;</strong></p><p>In this leaflet, several situations are described where Mirena should be removed, or where the reliability of Mirena may be decreased. In such situations you should either not have sex or you should use non-hormonal contraception such as condoms or another barrier method. Do not use rhythm or temperature methods. These methods can be unreliable because Mirena alters the monthly changes of body temperature and cervical mucus.</p><p>&nbsp;</p><p><strong>Mirena, like other hormonal contraceptives, does not protect against HIV infection (AIDS) or any other sexually transmitted disease<u>.</u></strong></p><p>&nbsp;</p><p>Do not use Mirena:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or think you might be pregnant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have tumors which depend on progestogen hormones to grow</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you currently or recurrently have a pelvic inflammatory disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an untreated infection of the cervix (neck of the womb)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an untreated lower genital tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had an infection of the womb after delivery</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had an infection of the womb after abortion or miscarriage during the past three months</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a condition associated with increased susceptibility to infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an untreated cell abnormality in the cervix</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a malignant tumor in the womb or cervix</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have unexplained abnormal uterine bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an abnormality of the womb or cervix, or fibroids that press on the cavity of the womb</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an acute liver disease or liver tumor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to levonorgestrel or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor before using Mirena.&nbsp;</p><p>&nbsp;</p><p>Consult a doctor who may decide to continue using Mirena or remove the system if any of the following conditions exists or appears for the first time while using Mirena:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine, with visual disturbances or other symptoms which may be signs of a transient cerebral ischemia (temporary blockage of the blood supply to the brain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exceptionally severe headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice (a yellowing of the skin, whites of the eyes, and/or nails)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Marked increase in blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe disease of arteries such as stroke or heart attack</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden blood clot (thrombosis) in a vein or in the lungs (pulmonary embolism).</p><p>&nbsp;</p><p>Symptoms or signs of thrombosis in the eye include unexplained partial or complete loss of vision, double vision, or some other unexplained visual disturbance.</p><p>&nbsp;</p><p>There is not yet consensus whether varicose veins and superficial thrombophlebitis have a role in venous thrombosis.</p><p>&nbsp;</p><p>Mirena may be used with caution in women who have congenital heart disease or valvular heart disease and are at risk of inflammation of the heart muscle.</p><p>&nbsp;</p><p>In diabetic users of Mirena, the blood glucose concentration should be monitored. However, there is usually no need to adjust the treatment in diabetic users of Mirena.</p><p>&nbsp;</p><p>Mirena is not the method of first choice for postmenopausal women with shrinking of the womb.</p><p>&nbsp;</p><p>Use of sanitary pads is recommended. If you are using tampons or a menstrual cup, you should change them with care so as not to pull the threads of Mirena.</p><p>&nbsp;</p><p><u>Breast cancer</u></p><p>&nbsp;</p><p>Do not use this preparation if you have or are suspected of having breast cancer. Users of combined oral contraceptives have been found to have a slightly increased (1.24 times the normal) risk of breast cancer. Since breast cancer is rare in women under 40 years of age, the increased risk of breast cancer is small compared with the overall breast cancer risk. The risk of having breast cancer diagnosed in progestin-only oral contraceptive users is possibly of a similar magnitude to that associated with combined oral contraceptives.</p><p>&nbsp;</p><p>The risk of breast cancer is increased in menopausal women using hormone replacement therapy (tablets or a preparation applied on the skin). The risk is higher in users of the combination of estrogen and progestin than in users of estrogen only. The product information on the estrogen preparation used in the treatment must also be read through.</p><p>&nbsp;</p><p>If you have benign lumps in your breast, mastopathy or an abnormal mammogram, or if you have a family history of breast cancer, your doctor should follow your condition carefully.</p><p>&nbsp;</p><p><u>Medical examination and precautions</u></p><p>&nbsp;</p><p>A physical examination before insertion may include a Pap smear if one has not been taken within three months, examination of the breasts and other tests, for example for infections and sexually transmitted diseases, as necessary. A gynecological examination should be performed to determine the position and size of the womb. Mirena is not suitable for use as postcoital contraceptive (used after intercourse).</p><p>&nbsp;</p><p><u>Effect on menstrual bleeding and bleeding disorders</u></p><p>&nbsp;</p><p>In women of fertile age, Mirena reduces the number of bleeding days and the volume of menstrual bleeding gradually during the use in more than half the women, and in some women menstrual bleedings will stop altogether. If you have not had a period for six weeks, the possibility of pregnancy must be excluded. For further information on the effects of Mirena on menstrual bleeding, see section 3. &quot;<!--[if supportFields]><span lang=""><span
style='mso-element:field-begin'></span> REF
Voiko_Mirena_vaikuttaa_kuukautiskiertoon \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Can Mirena affect my menstrual cycle<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000002900000056006F0069006B006F005F004D006900720065006E0061005F007600610069006B00750074007400610061005F006B00750075006B00610075007400690073006B0069006500720074006F006F006E000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=""><span
style='mso-element:field-end'></span></span><![endif]-->&quot;, &quot;<!--[if supportFields]><span lang=""><span style='mso-element:
field-begin'></span> REF Onko_epätavallista_että_kuukautiset_hävi \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Is it abnormal to have no periods<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B0200000008000000290000004F006E006B006F005F0065007000E40074006100760061006C006C0069007300740061005F00650074007400E4005F006B00750075006B0061007500740069007300650074005F006800E400760069000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=""><span
style='mso-element:field-end'></span></span><![endif]-->&quot; and &quot;<!--[if supportFields]><span lang=""><span style='mso-element:
field-begin'></span> REF Mistä_tiedän_olenko_raskaana \h <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->How will I know if I&#39;m pregnant<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001D0000004D00690073007400E4005F007400690065006400E4006E005F006F006C0065006E006B006F005F007200610073006B00610061006E0061000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=""><span
style='mso-element:field-end'></span></span><![endif]-->&quot;.</p><p>&nbsp;</p><p>Contact your doctor if you experience bleeding disorders during prolonged use or if bleeding starts after initiating estrogen replacement therapy.</p><p>&nbsp;</p><p><u>Infections</u></p><p><u>&nbsp;</u></p><p>The insertion tube helps to protect Mirena from contamination with micro-organisms during the insertion, and the Mirena inserter has been designed to minimize the risk of infections. Despite this, there is an increased risk of pelvic infection immediately after insertion and during the first month after insertion. Pelvic infections in IUS users are often related to sexually transmitted diseases. The risk of infection is increased if the woman or her partner has several sexual partners. Pelvic infections must be treated promptly. Pelvic infection may impair fertility and increase the risk of a future extrauterine pregnancy (pregnancy outside the womb).</p><p>&nbsp;</p><p>In extremely rare cases severe infection or sepsis (very severe infection which may be fatal) can occur shortly after insertion.</p><p>&nbsp;</p><p>Mirena must be removed if there are recurrent pelvic infections or infections of the lining of the womb, or if an acute infection is severe or does not respond to treatment within a few days.</p><p>&nbsp;</p><p>Consult a doctor without delay if you have persistent lower abdominal pain, fever, pain in conjunction with sexual intercourse, or abnormal bleeding. Severe pain or fever developing shortly after insertion may mean that you have a severe infection which must be treated immediately.</p><p>&nbsp;</p><p><u>Expulsion</u></p><p>&nbsp;</p><p>The muscular contractions of the womb during menstruation may sometimes push the IUS out of place or expel it. This is more likely to occur if you are overweight at the time of the IUS insertion or have a history of heavy periods. If the IUS is out of place, it may not prevent pregnancy and therefore, the risk of pregnancy is increased. If the IUS is completely expelled, you are not protected against pregnancy anymore.&nbsp;</p><p>Possible symptoms of an expulsion are pain and abnormal bleeding but Mirena may also come out without you noticing it. As Mirena decreases menstrual flow, an increase in menstruation may be a sign of an expulsion.</p><p>It is recommended that you check with your finger that the removal threads are in place, for example while having a shower. See also section 3 &quot;How to use Mirena&quot; and &quot;How can I tell whether Mirena is in place?&quot;. If you have signs indicative of an expulsion or you cannot feel the threads, you need to use another contraceptive (such as condoms), and consult a healthcare professional.</p><p>&nbsp;</p><p><u>Perforation</u></p><p><u>&nbsp;</u></p><p>Penetration or perforation of the wall of the womb may occur, most often during insertion, although it may not be detected until sometime later. A Mirena which has become lodged outside the cavity of the womb has reduced contraceptive efficacy and must be removed as soon as possible. You may need surgery to have Mirena removed. The risk of perforation of the uterine wall is increased in breast-feeding women and in women who had a delivery up to 36 weeks before insertion. In women with the uterus fixed and leaning backwards (a poorly moving, backwards tilted womb), the risk of perforation by the IUS may be increased. If you suspect a perforation, seek prompt advice from a healthcare professional and explain that you have had Mirena inserted. Especially if they are not the person who inserted it.</p><p>&nbsp;</p><p>Possible signs and symptoms of perforation may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe pain resembling menstrual cramps, or pain that is more severe than expected</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heavy bleeding (after insertion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain or bleeding which continues for more than a few weeks</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden changes in your periods</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain during sex</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can no longer feel the removal threads of Mirena (see section 3 &quot;<!--[if supportFields]><span lang=""><span
style='mso-element:field-begin'></span> REF Mistä_tiedän_että_Mirena_on_paikallaan
\h <span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->How can I tell whether Mirena is in place?<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B0200000008000000270000004D00690073007400E4005F007400690065006400E4006E005F00650074007400E4005F004D006900720065006E0061005F006F006E005F007000610069006B0061006C006C00610061006E000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=""><span
style='mso-element:field-end'></span></span><![endif]-->&quot;).</p><p>&nbsp;</p><p><u>Extrauterine pregnancy</u></p><p><u>&nbsp;</u></p><p>It is very rare to become pregnant while using Mirena. However, if you become pregnant while using Mirena, the risk that you could carry the fetus outside of your womb (have an extrauterine pregnancy) is slightly increased. About 1 in 1,000 women correctly using Mirena have an extrauterine pregnancy per year. This rate is lower than in women not using any contraception (about 3 to 5 in 1,000 women). The risk is higher if you have previously had an extrauterine pregnancy, surgery on the tubes from the ovaries to the womb, or a pelvic infection. An extrauterine pregnancy is a serious condition which calls for immediate medical attention. The following symptoms could mean that you may have an extrauterine pregnancy and you should see your doctor immediately:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your menstrual periods have ceased and then you start having persistent bleeding or pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have vague or very bad pain in your lower abdomen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have normal signs of pregnancy, but you also have bleeding and feel dizzy.</p><p><u>&nbsp;</u></p><p><u>Faintness</u></p><p><u>&nbsp;</u></p><p>Some women feel dizzy after Mirena is inserted. This is a normal physical response. Your doctor will tell you to rest for a while after you have had Mirena inserted.</p><p><u>&nbsp;</u></p><p><u>Enlarged ovarian follicles </u><u>(cells that surround a maturing egg in the ovary)</u></p><p>&nbsp;</p><p>Since the efficacy of Mirena is mainly due to its local effect, ovulatory cycles with follicular rupture usually occur in women of fertile age. Sometimes degeneration of the follicle is delayed and the development of the follicle may continue. Most of these follicles give no symptoms, although some may be accompanied by pelvic pain or pain during intercourse. These enlarged follicles may require medical attention, but they usually disappear on their own.</p><p><em><u>&nbsp;</u></em></p><p><u>Psychiatric disorders</u></p><p>&nbsp;</p><p>Some women using hormonal contraceptives including Mirena have reported depression or depressed mood. Depression can be serious and may sometimes lead to suicidal thoughts. If you experience mood changes and depressive symptoms, contact your doctor for further medical advice as soon as possible.</p><p>&nbsp;</p><p>Other medicines and Mirena</p><p>&nbsp;</p><p>Since the mechanism of action of Mirena is mainly local, intake of other medicines is not believed to have a major effect on the contraceptive efficacy of Mirena. Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>&nbsp;</p><p>Mirena must not be used if you are pregnant or think you may be pregnant.</p><p>&nbsp;</p><p>It is very rare for a woman to become pregnant with Mirena in place. If Mirena comes out, you are no longer protected and must use another form of contraception until you see your doctor.</p><p>&nbsp;</p><p>Some women may not have their periods while using Mirena. Not having a period is not necessarily a sign of pregnancy. If you do not have your period and have other symptoms of pregnancy (for example nausea, tiredness, breast tenderness), you should see your doctor for an examination and have a pregnancy test.</p><p>&nbsp;</p><p>If you become pregnant with Mirena in place, you should contact your healthcare professional immediately to have Mirena removed. The removal may cause a miscarriage. However, if Mirena is left in place during pregnancy, not only is the risk of having a miscarriage higher, but also the risk of preterm labor. If Mirena cannot be removed, talk with your healthcare professional about the benefits and risks of continuing the pregnancy.</p><p>If the pregnancy is continued, you will be closely monitored during your entire pregnancy and you should contact your doctor if you experience stomach cramps, pain in your stomach, or fever.</p><p>Mirena contains a hormone called levonorgestrel, and there have been isolated reports of effects on the genitalia of female babies if exposed to levonorgestrel while in the womb.</p><p><strong>&nbsp;</strong></p><p>Mirena can be used during breast-feeding. Levonorgestrel has been identified in small quantities in the breast milk of nursing women (0.1% of the dose is transferred to the infant). Hormonal contraceptives are not recommended as the method of first choice during breast-feeding, but progestogen-only methods are considered to comprise the next choice category after non-hormonal methods. There appears to be no negative effects on infant growth or development when using Mirena six weeks after delivery. Progestogen-only methods do not appear to affect the quality of breast milk.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p>Driving and using machines</p><p>&nbsp;</p><p>No known effects.</p><p>&nbsp;</p><p>Mirena contains barium sulphate</p><p>&nbsp;</p><p>The T-frame of Mirena contains barium sulphate, which makes it visible in X-ray examination.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to use Mirena</p><p>&nbsp;</p><p>How effective is Mirena?</p><p>&nbsp;</p><p>The probability of failed contraceptive efficacy during the use of Mirena is about 0.2% in the first year of use. The risk of pregnancy may increase in case the IUS is displaced or it perforates the uterine wall (see section 2 &quot;<!--[if supportFields]><span lang="" style='font-weight:
normal'><span style='mso-element:field-begin'></span> REF
Lääketieteellinen_tutkimus_ja_varotoimet \h<span style='mso-spacerun:yes'> 
</span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Medical examination and precautions<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B0200000008000000290000004C00E400E4006B0065007400690065007400650065006C006C0069006E0065006E005F007400750074006B0069006D00750073005F006A0061005F007600610072006F0074006F0069006D00650074000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang="" style='font-weight:
normal'><span style='mso-element:field-end'></span></span><![endif]-->&quot;).</p><p>&nbsp;</p><p>In the treatment of excessive menstrual bleeding, Mirena causes a strong reduction in menstrual bleeding already within three months. Some users will have no periods at all.</p><p>&nbsp;</p><p>When should Mirena be inserted?</p><p>&nbsp;</p><p>You can have Mirena inserted within seven days from the onset of menstrual bleeding. The IUS can also be inserted immediately after a first-trimester abortion provided that there are no genital infections. The IUS should be inserted only after the womb has returned to its original size after delivery, and not earlier than six weeks after delivery (see section 2 &rdquo;<!--[if supportFields]><span
lang=""><span style='mso-element:field-begin'></span> REF Puhkeaminen \h<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Perforation<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000C0000005000750068006B00650061006D0069006E0065006E000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=""><span
style='mso-element:field-end'></span></span><![endif]-->&rdquo;). Mirena can be replaced by a new Mirena at any time of the cycle.</p><p>&nbsp;</p><p>When Mirena is used to protect the lining of the womb during estrogen replacement therapy, it can be inserted at any time in a woman who has no monthly bleeding, or during the last days of menstruation or withdrawal bleeding.</p><p>&nbsp;</p><p>Mirena should only be inserted by healthcare professionals who are experienced in Mirena insertions or have undergone sufficient training for Mirena insertion.</p><p>&nbsp;</p><p>How is Mirena inserted?</p><p>&nbsp;</p><p>After a gynecological examination, an instrument called a speculum is inserted into the vagina, and the cervix is cleansed with an antiseptic solution. The IUS is then inserted into the womb via a thin, flexible plastic tube. Local anesthesia may be applied to the cervix to relieve pain, if necessary.</p><p>&nbsp;</p><p><u>Some women may experience pain and dizziness after insertion. If these do not pass within half an hour in the resting position, the IUS may not be correctly positioned. An examination should be carried out and the IUS removed, if necessary.</u></p><p><strong><em>&nbsp;</em></strong></p><p>When should I see a doctor?</p><p>&nbsp;</p><p>You should have your IUS checked 4&ndash;12 weeks after insertion, and thereafter regularly, at least once a year. Your doctor will determine how often and what kinds of check-ups are required in your particular case. In addition, you should contact your doctor if any of the following occurs:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You no longer feel the threads in your vagina with your fingers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can feel the lower end of the IUS with your fingers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You think you may be pregnant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have persistent abdominal pain, fever, or unusual discharge from the vagina</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You or your partner feel pain or discomfort during sexual intercourse</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are sudden changes in your menstrual periods (for example, if you first have little or no menstrual bleeding, and then you start having persistent bleeding or pain, or you start bleeding heavily)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have other medical problems, such as migraine headaches or intense headaches that recur, sudden problems with vision, jaundice, or high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You experience any of the conditions mentioned in section 2 &quot;Before you use Mirena&quot;.</p><p>Tell the healthcare professional that you have Mirena inserted. Especially if they are not the person who inserted it.</p><p>&nbsp;</p><p>For how long can Mirena be used?</p><p>&nbsp;</p><p>Mirena is effective for 8 years when used for prevention of pregnancy (contraception). Are you using Mirena for this reason? If so, your Mirena should be removed or replaced after 8 years at the latest.</p><p>Mirena is effective for 5 years when used for heavy menstrual bleeding. Are you using Mirena for this reason? If so, your Mirena should be removed or replaced when the heavy menstrual bleeding returns or after 8 years at the latest.</p><p>Mirena is effective for 5 years when used for menstrual pain or as progestogen treatment during menopausal hormone replacement therapy. Are you using Mirena for either of these reasons? If so, your Mirena should be removed or replaced after 5 years at the latest.</p><p>&nbsp;</p><p>If you like, you may have a new Mirena inserted when the old one is removed.</p><p>&nbsp;</p><p>What if I want to become pregnant or have Mirena removed for another reason?</p><p>&nbsp;</p><p>The IUS can easily be removed at any time by your doctor, after which pregnancy is possible. Removal is usually a painless procedure. Fertility returns to normal after removal of Mirena.</p><p>&nbsp;</p><p>If pregnancy is not desired, Mirena should not be removed after the seventh day of the menstrual cycle (monthly period) unless contraception is covered with other methods (e.g. condoms), for at least seven days before the removal. If you have irregular periods or no periods, you should use barrier methods of contraception for seven days before the removal of Mirena until your menstruation reappears. A new Mirena can also be inserted immediately after removal, in which case no additional protection is needed.</p><p>&nbsp;</p><p>Can I become pregnant after stopping the use of Mirena?</p><p>&nbsp;</p><p>Yes. After Mirena is removed, it does not interfere with your normal fertility. You may become pregnant during the first menstrual cycle after Mirena is removed.</p><p>&nbsp;</p><p>Can Mirena affect my menstrual cycle?</p><p>&nbsp;</p><p>Mirena does affect your menstrual cycle. It can change your menstrual periods in such a way that you have spotting (a small amount of blood loss), shorter or longer periods, lighter or heavier bleeding, or no bleeding at all.</p><p>&nbsp;</p><p>Many women have frequent spotting or light bleeding in addition to their periods for the first 3&ndash;6 months after they have Mirena inserted. Some women may have heavy or prolonged bleeding during this time. Please inform your doctor if this persists.</p><p>&nbsp;</p><p>Overall, you are likely to have a gradual reduction in the number of bleeding days and in the amount of blood lost each month. Some women eventually find that periods stop altogether. As the amount of menstrual bleeding is gradually reduced during the use of Mirena, most women experience an increase in their blood hemoglobin value.</p><p>&nbsp;</p><p>When the IUS is removed, periods return to normal.</p><p>&nbsp;</p><p>Is it abnormal to have no periods?</p><p>&nbsp;</p><p>Not when you are using Mirena. If you find that you do not have periods with Mirena, it is because of the effect of the hormone on the lining of the womb. The monthly thickening of the lining does no longer happen. Therefore, there is nothing to come away as a period. It does not necessarily mean that you have reached menopause or are pregnant. Your own hormone levels remain normal.</p><p>&nbsp;</p><p>How will I know if I&#39;m pregnant?</p><p>&nbsp;</p><p>Pregnancy is unlikely in women using Mirena, even if they do not have periods.</p><p>&nbsp;</p><p>If you have not had a period for six weeks and are concerned, then consider having a pregnancy test. If this is negative, there is no need to carry out another test unless you have other signs of pregnancy, e.g. nausea, tiredness or breast tenderness.</p><p>&nbsp;</p><p>Can Mirena cause pain or discomfort?</p><p>&nbsp;</p><p>Some women feel pain (like menstrual cramps) in the first few weeks after insertion. You should return to your doctor if you have severe pain or if the pain continues for more than three weeks after you have had Mirena inserted.</p><p>&nbsp;</p><p>Will Mirena interfere with sexual intercourse?</p><p>&nbsp;</p><p>Neither you nor your partner should feel the IUS during intercourse. If you do, intercourse should be avoided until your doctor has checked that the IUS is still in the correct position.</p><p>&nbsp;</p><p>How long should I wait to have sexual intercourse after the insertion?</p><p>&nbsp;</p><p>To give your body a rest, it is best to wait about 24 hours after having Mirena inserted before having sexual intercourse. However, as soon as it is inserted, Mirena will prevent pregnancy.</p><p>&nbsp;</p><p>Can I use tampons or a menstrual cup?</p><p>&nbsp;</p><p>Use of sanitary pads is recommended. If you are using tampons or a menstrual cup, you should change them with care so as not to pull the threads of Mirena.</p><p>&nbsp;</p><p>If you think you may have pulled Mirena out of place (see &rdquo;When should I see my doctor&rdquo; for possible signs), avoid intercourse or use a barrier contraceptive (such as condoms), and contact your doctor</p><p>&nbsp;</p><p>What happens if Mirena comes out by itself?</p><p>&nbsp;</p><p>It is rare but possible for Mirena to come out during your menstrual period without you noticing. An unusual increase in the amount of bleeding during your period could mean that Mirena has come out through your vagina. It is also possible for part of Mirena to come out of your womb (you and your partner may notice this during sexual intercourse). If Mirena comes out completely or partially, you will not be protected from pregnancy.</p><p>&nbsp;</p><p>&nbsp;</p><p>How can I tell whether Mirena is in place?</p><p>&nbsp;</p><p>You can check yourself if the threads are in place. Gently put a finger into your vagina and feel for the threads at the end of your vagina near the opening of the womb.</p><p>&nbsp;</p><p><strong>Do not pull the threads</strong> because you may accidentally pull out Mirena. If you cannot feel the threads, this may indicate that the IUS has come out by itself or it has perforated the uterine wall. In this case you should use a barrier method (such as condoms) and contact your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</p><p>&nbsp;</p><p>Like all medicines, Mirena can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>In addition to the possible side effects already mentioned in other sections (e.g. section 2 &quot;What you need to know before you use Mirena&quot;), here is a list of possible side effects by the parts of the body they affect and by how common they are:</p><p>&nbsp;</p><p><strong>Very common</strong> (in more than 1 out of 10 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uterine/vaginal bleeding (including spotting), irregular periods (oligomenorrhea) and absence of bleeding (amenorrhea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged ovarian follicles (see Section 2 &ldquo;<!--[if supportFields]><span
lang=""><span style='mso-element:field-begin'></span> REF
Laajentuneet_munarakkulat \h<span style='mso-spacerun:yes'>  </span>\*
MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Enlarged ovarian follicles<u> </u><!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000001A0000004C00610061006A0065006E00740075006E006500650074005F006D0075006E006100720061006B006B0075006C00610074000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=""><span
style='mso-element:field-end'></span></span><![endif]-->&rdquo;)</p><p><strong>&nbsp;</strong></p><p><strong>Common</strong> (in more than 1 out of 100 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depressive mood / depression, nervousness, decreased libido</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain, nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acne</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pelvic pain, dysmenorrhea (painful menstruation), vaginal discharge, vulvovaginitis (infection of the external genital organs or vagina), breast tenderness, breast pain, expulsion of the IUS</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight increase</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon</strong> (in less than 1 out of 100 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal distension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss, hirsutism (excessive body hair), severe itching, eczema (skin infection), liver spots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pelvic inflammatory disease (upper genital tract infection, above the cervix), infection of the endometrium, infection of the cervix / Pap smear result normal, class II</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Edema (swelling)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Perforation of the wall of the womb</p><p><strong>&nbsp;</strong></p><p><strong>Rare </strong>(in less than 1 out of 1,000 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, urticaria (hives)</p><p>&nbsp;</p><p>Cases of sepsis (very severe systemic infection, which may be fatal) have been reported following insertion of an intrauterine contraceptive.</p><p>&nbsp;</p><p>If you become pregnant while using Mirena, there is a possibility that the pregnancy is outside the womb (see section 2 &rdquo;<!--[if supportFields]><span
lang=""><span style='mso-element:field-begin'></span> REF Kohdunulkoinen_raskaus
\h<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->Extrauterine pregnancy<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B0200000008000000170000004B006F006800640075006E0075006C006B006F0069006E0065006E005F007200610073006B006100750073000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=""><span
style='mso-element:field-end'></span></span><![endif]-->&rdquo;).</p><p>&nbsp;</p><p>Cases of breast cancer have also been reported (frequency unknown).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Mirena</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the package. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the pack and other information</p><p>&nbsp;</p><p>What Mirena contains</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is levonorgestrel. One intrauterine delivery system contains 52&nbsp;mg of levonorgestrel.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: hormone-elastomer core (polydimethylsiloxane and silica), T-body (polyethylene and barium sulfate), removal thread (polyethylene and iron oxide (E 172)).</p><p><!--[if !supportLists]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Mirena looks like and contents of the pack
Pack size: One sterile intrauterine delivery system


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing authorization holder</strong></p><p>Bayer Oy</p><p>Turku, Finland.</p><p><strong>Manufacturer</strong></p><p>Bayer Oy</p><p>47 Pansiontie street</p><p>20210 Turku &ndash; Finland.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised on 28 October 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ميرينا هو لولب هرموني على شكل حرف تي (T) الذي يطلق بعد إدخاله (زرعه) هرمون الليفونورجستريل داخل الرحم. الغرض من الشكل تي (T) هو ضبط اللولب على حسب شكل الرحم. الذراع الرأسي الأبيض لجسم اللولب على شكل تي (T) يحمل مستودع دواء يحتوي على ليفونورجستريل. خيطين بنيان للإزالة مربوطان بالحلقة الموجودة في الطرف السفلي للذراع الرأسي.</p><p dir="RTL">يستخدم ميرينا لمنع الحمل، للنزف الحيضي الزائد، الآم الحيض، و كعلاج بالبروجستوجين أثناء المعالجة بالإعاضة الهرمونية لانقطاع الطمث.</p><p dir="RTL">يحتوي ميرينا على ليفونورجستريل الذي يمكن في بعض الأحيان أن يستخدم في علاج أمراض أخرى غير تلك المذكورة في هذه النشرة. أسألي طبيبك أو الصيدلي أو غيرهم من الرعاية الصحية المهنية للحصول على المشورة، إذا لزم الأمر، و دائماً اتبعي تعليماتهم.</p><p dir="RTL"><u>الأطفال و المراهقات</u></p><p dir="RTL">ميرينا ليس مُعَد للاستخدام قبل أول نزف حيضي (الدورة الشهرية الأولى).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ملاحظات عامة</strong></p><p dir="RTL">قبل أن تبدئي باستخدام ميرينا، سوف يسألك طبيبك بعض الأسئلة عن تاريخك الطبي الشخصي و تاريخ أقاربك المقربين.</p><p dir="RTL">في هذه النشرة، وصف لمواقف متعددة يجب فيها إزالة ميرينا أو يمكن أن ينخفض فيها الاعتماد على الميرينا كمانع للحمل. في مثل هذه الحالات يجب إما عدم الاتصال الجنسي أو يجب استخدام مانع للحمل غير هرموني مثل العازل الطبي أو وسائل إعاقة اخرى. لا تستخدمي وسائل النظم (التعاقب المنتظم) او وسيلة درجة الحرارة. هذه الوسائل يمكن ان تكون غير موثوقة لأن ميرينا يبدل التغيرات الشهرية لدرجة حرارة الجسم و لمخاط عنق الرحم.</p><p dir="RTL"><strong>ميرينا مثل كل موانع الحمل الهرمونية، لا يحمي من مرض الإيدز (عدوى فيروس نقص المناعة البشرية) او أي مرض ينتقل عن طريق الجنس.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تستخدمي ميرينا إذا كان لديك أي من الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملا أو يوجد اشتباه بالحمل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اورام تعتمد في نموها على هرمون البروجستوجن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض التهابي حوضي حالي أو متكرر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك عدوى لعنق الرحم لم يتم علاجها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك عدوى للجهاز التناسلي السفلي لم يتم علاجها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك في الماضي عدوى في الرحم بعد الولادة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك في الماضي عدوى في الرحم بعد الولادة أو الإجهاض خلال الثلاثة شهور الأخيرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حالة تجعلك أكثر عرضة للعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك خلايا غير طبيعية في عنق الرحم لم يتم علاجها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك ورم سرطاني في الرحم أو في عنق الرحم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك نزف من الرحم غير طبيعي لم يتم معرفة سببه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تشوه للرحم أو لعنق الرحم، أو ورم ليفي يضغط على جوف الرحم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض حاد للكبد أو ورم للكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية لليفونورجستريل او لأي مكونات اخرى لهذا الدواء (المذكورة في الجزء 6).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات و الاحتياطات</strong></p><p dir="RTL">تحدثي إلى طبيبك أو الصيدلي قبل تناول ميرينا:</p><p dir="RTL">إذا كانت أي من الحالات التالية موجودة أو تظهر لأول مرة خلال استخدام ميرينا، استشيري الطبيب الذي يمكن أن يقرر استمرار استخدام ميرينا أو ازالة اللولب:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الصداع النصفي، مع اضطرابات بصرية أو غيرها من الأعراض التي قد تكون دلائل على وجود نقص التروية الدماغية العابرة (انسداد مؤقت في تدفق الدم إلى الدماغ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صداع شديد استثنائي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يرقان (اصفرار الجلد، بياض العيون و / أو الأظافر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ملحوظة لضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مرض شديد في الشرايين مثل سكتة دماغية أو نوبة قلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تجلط دم مفاجئ (تجلط دموي) داخل الوريد أو في الرئتين (انسداد رئوي).</p><p dir="RTL">أعراض أو علامات لتجلط دموي في العين تشمل فقدان شامل أو جزيء للإبصار غير مفهوم، رؤية مزدوجة، أو بعض الاضطرابات الإبصارية الاخرى الغير مفهومة.</p><p dir="RTL">حتى الآن لا يوجد اتفاق اجماعي في الرأي ما إذا كانت دوالي الأوردة و التهابات الأوردة بسبب التجلط السطحي لهم دور في التجلط الدموي الوريدي.</p><p dir="RTL">يمكن استخدام ميرينا بحذر لدى النساء اللاتي لديهن مرض قلبي خلقي أو مرض قلبي صمامي والمعرضات لخطر الالتهاب لعضلة القلب.</p><p dir="RTL">يجب مراقبة تركيز الجلوكوز في الدم، لدى مرضى الداء السكري اللاتي يستخدمن ميرينا. مع ذلك، لا يوجد عموماً احتياج الى تعديل العلاج لمرضى الداء السكري بينما يتم استخدام ميرينا.</p><p dir="RTL">ميرينا ليس الخيار الأول للنساء بعد انقطاع الطمث مع تقلص الرحم.</p><p dir="RTL">يوصى باستخدام الفوط الصحية. إذا كنت تستخدمين السدادات القطنية أو كأس الحيض ، فيجب عليك تغييرها بعناية حتى لا تسحب خيوط ميرينا.</p><p dir="RTL"><u>سرطان الثدي</u></p><p dir="RTL">لا تستخدمي هذا المنتج إذا كان لديك أو يشتبه في وجود سرطان الثدي. تم العثور لدى مستخدمي وسائل منع الحمل المركبة و التي يتم تناولها عن طريق الفم أن لديهن زيادة طفيفة في مخاطرة الاصابة بسرطان الثدي (1.24 مرة عن المعدل العادي). حيث أن سرطان الثدي أمر نادر الحدوث لدى النساء دون 40 عاماً من العمر، فإن زيادة مخاطرة الاصابة بسرطان الثدي صغيرة مقارنة مع المخاطرة الاجمالية للإصابة بسرطان الثدي. ربما تكون مقدار المخاطرة في تشخيص وجود سرطان الثدي لدى مستخدمي وسائل منع الحمل التي يتم تناولها عن طريق الفم و التي تحتوي فقط على بروجستين، مماثلة لتلك المخاطرة المرتبطة مع وسائل منع الحمل المركبة و التي يتم تناولها عن طريق الفم.</p><p dir="RTL">تزداد مخاطرة الاصابة بسرطان الثدي لدى النساء بعد انقطاع الطمث و اللاتي تستخدمن المعالجة بالإعاضة الهرمونية (أقراص أو مستحضر يستخدم استخدام موضعي على الجلد). المخاطرة أعلى لدى المستخدمات لمزيج من الاستروجين والبروجستين من المستخدمات للاستروجين فقط. يجب أيضاً أن تقرأ بعناية المعلومات الخاصة بالمستحضر الذي يحتوي على استروجين و الذي يستخدم في العلاج.</p><p dir="RTL">إذا كان لديك كتل حميدة في الثدي، أو تغيير في غدد الثدي أو لديك أشعة تصويرية للثدي بها خلل أو إذا كان لديك تاريخ مرضي عائلي للإصابة بسرطان الثدي، يجب على طبيبك أن يتابع حالتك بعناية.</p><p dir="RTL"><u>الفحص الطبي و الاحتياطات</u></p><p dir="RTL">يمكن أن يشمل الفحص الطبي قبل الزرع (الإدخال) فحص خلايا عنق الرحم و إذا لم يتم أخذ عينة من عنق الرحم خلال ثلاثة شهور، حسب الضرورة يتم فحص الثدي و اختبارات أخرى، مثلاً اختبارات للعدوى و للأمراض المنقولة جنسياً،. يجب القيام بفحص نسائي لتحديد وضع و حجم الرحم. لا يصلح استخدام ميرينا كمانع للحمل بعد الجماع.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>تأثير ميرينا على الدورة الشهرية و اضطرابات النزف</u></p><p dir="RTL">خلال استخدام ميرينا لدى النساء اللاتي في سن الإنجاب، تقل عدد أيام النزف و حجم النزف الشهري تدريجياً، و ذلك لدى أكثر من نصف النساء، و يحدث لدى بعض النساء أن يتوقف النزف الشهري تماماً. إذا لم تكن لديك نزيف طمثي لمدة ستة أسابيع، يجب أن تستبعدي احتمال وجود الحمل. لمزيد من المعلومات عن آثار ميرينا على نزف الطمث، انظر الجزء 3. هل يمكن لميرينا أن يكون له تأثير على نزف الطمث؟، هل هو غير طبيعي أن لا يحدث لديهم نزف الطمث؟ و كيفية معرفة وجود الحمل؟</p><p dir="RTL">اتصلي بطبيبك إذا عانيتي من اضطرابات النزف أثناء الاستعمال لفترة طويلة أو إذا بدأ النزف بعد بدء المعالجة بالإعاضة الهرمونية باستخدام الاستروجين.</p><p dir="RTL"><u>العدوى</u></p><p dir="RTL">يساعد أنبوب الإدخال من حماية ميرينا من التلوث بكائنات مجهرية أثناء الإدخال، و تم تصميم أداة إدخال ميرينا لتقليل التعرض لمخاطرة العدوى. على الرغم من ذلك، توجد زيادة في مخاطر التعرض لعدوى الحوض مباشرة بعد الإدخال و خلال الشهر الأول بعد الإدخال. عدوى الحوض لدى مستخدمي اللولب الهرموني غالبا ما تكون مرتبطة بالأمراض المنقولة جنسياً. التعرض لخطر العدوى يزداد إذا كانت المرأة أو زوجها لهما عدة شركاء في الجنس. يجب علاج عدوى الحوض فوراً. يمكن لعدوى الحوض أن تضعف الإخصاب و تزيد من مخاطرة التعرض للحمل خارج الرحم في المستقبل.</p><p dir="RTL">في حالات نادرة للغاية يمكن أن تحدث عدوى حادة أو تعفن للدم (عدوى حادة جداً و التي قد تكون قاتلة) بعد فترة قصيرة من الإدخال.</p><p dir="RTL">يجب إزالة ميرينا إذا حدث تكرار لعدوى التهاب الحوض او عدوى التهاب بطانة الرحم أو أن كانت العدوى الحادة شديدة و لم تستجيب للعلاج خلال بضعة أيام.</p><p dir="RTL">استشيري طبيبك، بدون تأخير، إذا كان لديك ألم مستمر أسفل البطن، ارتفاع لدرجة حرارة الجسم، حدوث ألم أثناء الجماع، أو نزف غير طبيعي. إذا حدث ألم شديد أو ارتفاع لدرجة حرارة الجسم بعد وقت قصير من الإدخال قد يعني أن لديك عدوى حادة التي يجب أن تعالج على الفور.</p><p dir="RTL"><u>الطرد</u></p><p dir="RTL">قد تؤدي التقلصات العضلية للرحم أثناء الحيض أحيانًا إلى إخراج اللولب الهرموني (IUS) من مكانه أو طرده. قد يحدث الطرد إذا كنتِ تعانين من زيادة الوزن وقت إدخال اللولب الهرموني (IUS) أو كان لديكِ تاريخ من دورات الحيض الغزيرة. إذا كان اللولب الهرموني (IUS) &nbsp;في غير مكانه، فقد لا يمنع الحمل وبالتالي يزداد خطر الحمل. إذا تم طرد اللولب الهرموني (IUS) تمامًا ، فلن تكوني محمية من الحمل بعد الآن.</p><p dir="RTL">الأعراض المحتملة للطرد هي الألم والنزيف غير الطبيعي ولكن قد يخرج اللولب (ميرينا) أيضًا دون أن تلاحظيه. نظرًا لأن تدفق الحيض ينخفض عادةً أثناء استخدام ميرينا، فقد تكون زيادة تدفق الدورة الشهرية علامة على الطرد. يوصى بالتحقق بإصبعك من أن خيوط الإزالة في مكانها ، على سبيل المثال أثناء الاستحمام. انظري أيضًا القسم 3 &laquo;كيفية استخدام ميرينا&raquo; و &laquo;كيف يمكنني معرفة ما إذا كان ميرينا في مكانه؟&raquo;. إذا كانت لديك علامات تدل على الطرد أو لا تشعرين بالخيوط ، فأنت بحاجة إلى استخدام مانع للحمل (مثل الواقي الذكري) ، واستشارة أخصائي الرعاية الصحية.</p><p dir="RTL"><u>ثقب الرحم</u></p><p dir="RTL">قد يحدث اختراق أو ثقب لجدار الرحم، غالبًا خلال الزرع (الإدخال)، على الرغم من أنه قد لا يتم اكتشافه إلا في وقت لاحق. اذا استقر ميرينا خارج تجويف الرحم فإن فاعليته تنخفض في منع الحمل و يجب إزالته بأسرع ما يمكن. قد تكون هناك حاجة إلى عملية جراحية لإزالة&nbsp; ميرينا. مخاطر اختراق جدار الرحم يمكن ان تزداد إذا تم زرع (إدخال) ميرينا للنساء المرضعات و للنساء اللواتي انجبن حتى 36 أسبوعا قبل الزرع. و يمكن ان تزداد مخاطر الاختراق في النساء اللواتي لديهن الرحم ثابت ومائل للخلف. (رحم متحرك بشكل ضعيف و مائل إلى الخلف).</p><p dir="RTL">إذا كنت تشكين في وجود ثقب، اتصلي بطبيب مختص للحصول على المشورة دون تأخير، ووضحي له انه قد تم زرع ميرينا لك، خاصة إذا لم يكن هو من قام بزرعها لك</p><p dir="RTL">ويمكن أن تشمل علامات وأعراض ثقب الرحم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد يشبه تقلصات الدورة الشهرية، أو ألم أكثر حدة مما هو متوقعا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نزيف حاد (بعد الزرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو نزيف مستمر لأكثر من بضعة أسابيع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات مفاجئة في الدورة الشهرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم أثناء الاتصال الجنسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا يمكنك الشعور بخيوط الإزالة لميرينا (انظر القسم 3 &laquo; كيف يمكن أن اعرف أن ميرينا في موضعه؟&raquo; )</p><p dir="RTL"><u>الحمل خارج الرحم</u></p><p dir="RTL">أنه من النادر جداً أن يحدث حمل أثناء استخدام ميرينا. مع ذلك، إذا أصبحت حاملا بينما تستخدمين ميرينا، فإن مخاطرة امكانية أن تحملي الجنين خارج الرحم (الحمل خارج الرحم) تزداد قليلاً. تقريباً 1 في 1000 سيدة تستخدم ميرينا كما ينبغي يحدث لديها حمل خارج الرحم في السنة. هذا المعدل منخفض عن ذلك لدى السيدات اللاتي لا تستخدمن أي مانع للحمل (تقريباً 3 إلى 5 في 1000 سيدة). المخاطرة اعلى إذا كان لديك في الماضي حمل خارج الرحم، جراحة لأنابيب بوق المبيض أو عدوى للحوض. الحمل خارج الرحم حالة خطيرة تتطلب فورا عناية طبية. الأعراض الآتية يمكن أن تعني احتمال وجود حمل خارج الرحم و يجب عليك زيارة الطبيب فوراً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; توقف فترات الحيض ثم يبدأ نزف مستمر أو آلم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لديك ألم غير واضح أو سيئ جداً أسفل البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لديك علامات طبيعية للحمل، لكن أيضاً لديك نزف و تشعرين بالدوخة (الدوار).</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>إغماء</u></p><p dir="RTL">بعض النساء تشعرن بالدوخة بعد إدخال ميرينا. هذه استجابة بدنية طبيعية للجسم. سوف يخبرك طبيبك بأن تستريحي لمدة قصيرة بعد إدخال ميرينا.</p><p dir="RTL"><u>زيادة حجم الجريبات المبيضية (خلايا تحيط بالبويضة التي تنضج في المبيض)</u></p><p dir="RTL">بما أن فاعلية ميرينا هو في الدرجة الأولى بسبب تأثيره الموضعي، فإن الدورات الإباضية مع تمزق جريبي تحدث عادة للنساء في سن الخصوبة. أحياناً يحدث تأخير لانحلال الجريب و يمكن أن يستمر تطور الجريب. معظم هذه الجريبات لا تحدث أعراض، مع أن بعضها يمكن أن يصاحبها آلام في الحوض أو ألم أثناء الاتصال الجنسي. هذه الجريبات المتضخمة يمكن أن تحتاج لاهتمام طبي، و لكن عادة تختفي من تلقاء نفسها.</p><p dir="RTL"><u>اضطرابات نفسية</u></p><p dir="RTL">بعض النساء اللاتي يستخدمن موانع الحمل الهرمونية بما في ذلك ميرينا أبلغن عن اعراض اكتئاب أو مزاج مكتئب. قد يكون الاكتئاب خطيرًا وقد يؤدي أحيانًا إلى أفكار انتحارية. إذا واجهتي تغيرات في المزاج أوأعراض اكتئاب، فاتصلي بطبيبك للحصول على مزيد من النصائح الطبية في أقرب وقت ممكن.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ميرينا و تناول أدوية أخرى</strong></p><p dir="RTL">بما أن آلية عمل ميرينا موضعية، في الغالب، فإن تناول أدوية أخرى لا يعتقد أن يكون له تأثير رئيسي على فاعلية منع الحمل لميرينا. يجب إبلاغ طبيبك أو الصيدلي إذا كنت تتناولين الآن، او تناولت حديثاً أو قد تتناولين قريباً أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل و الرضاعة الطبيعية</strong></p><p dir="RTL">يجب عدم استخدام ميرينا إذا كنت حاملا أو تشتبهين أن تكونين حاملاً.</p><p dir="RTL">من النادر جدا أن تصبح المرأة حاملا مع وجود ميرينا في مكانه. لكن إذا خرج ميرينا من مكانه، فأنت غير محمية و يجب عليك استخدام أسلوب آخر لمنع الحمل لحين ذهابك لطبيبك.</p><p dir="RTL">من الممكن لبعض النساء أن لا يحدث لديهن دورات طمث خلال استخدامهن ميرينا. عدم حدوث دورة الطمث ليس بالضرورة علامة للحمل. إذا لم تحدث دورة طمث و لديك أعراض أخرى للحمل (مثلاً غثيان، تعب، ألم عند الضغط على الثدي)، يجب عليك زيارة طبيبك للفحص و للقيام باختبار للحمل.</p><p dir="RTL">إذا حدث حمل مع وجود ميرينا في مكانه، فيجب عليك الاتصال بأخصائي الرعاية الصحية الخاص بك على الفور لإزالة ميرينا. قد تؤدي الإزالة إلى الإجهاض. ومع ذلك، إذا تُركت ميرينا في مكانها أثناء الحمل، فلن يزيد هذا من خطر حدوث إجهاض فحسب، بل يزيد أيضًا من مخاطر الولادة المبكرة. إذا تعذر إزالة ميرينا، فتحدثي مع أخصائي الرعاية الصحية الخاص بك حول فوائد ومخاطر استمرار الحمل، والآثار المحتملة للهرمون على نمو الطفل</p><p dir="RTL">يمكن استخدام ميرينا أثناء الرضاعة من الثدي. تم الكشف عن كميات صغيرة من ليفونورجستريل في حليب الثدي لنساء مرضعات. (0.1 % من الجرعة تنتقل للرضيع). لا ينصح بموانع الحمل الهرمونية كاختيار أول أثناء الرضاعة من الثدي، و لكن أساليب منع الحمل التي تحتوي على بروجستوچين فقط تعتبر فئة الاختيار التالية بعد الأساليب الغير هرمونية. من الظاهر أنه لا يوجد تأثيرات ضارة على نمو الطفل أو تطوره عندما يستخدم ميرينا ستة أسابيع بعد الولادة. من الظاهر أن الأساليب التي تحتوي على بروجستوچين فقط ليس لها تأثير على جودة حليب الثدي.</p><p dir="RTL">إذا كنت حاملا أو ترضعين طبيعي (من الثدي)، تعتقدين أن تكونين حاملا أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة و استخدام الآلات</strong></p><p dir="RTL">لا توجد آثار معروفة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ميرينا يحتوي على كبريتات الباريوم</strong></p><p dir="RTL">إن إطار الشكل تي (T) لميرينا يحتوي على كبريتات الباريوم، التي تجعله مرئي في الفحص بأشعة إكس (X).</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي درجة فاعلية ميرينا؟</strong></p><p dir="RTL">احتمال فشل فاعلية منع الحمل خلال استخدام ميرينا هي تقريباً 0.2 %&nbsp; في العام الأول من الاستخدام. مخاطرة حدوث الحمل يمكن أن تزداد في حالة إزاحة اللولب الهرموني من مكانه أو تم اختراق جدار الرحم (انظر الجزء 2 &laquo;الفحص الطبي و الاحتياطات&raquo;).</p><p dir="RTL">في علاج النزف الحيضي الزائد، يسبب ميرينا انخفاض قوي للنزف الحيضي بعد مضي ثلاثة شهور من استخدامه. لن يحدث لبعض المستخدمات دورات طمث مطلقاً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>متى يجب زرع ميرينا؟</strong></p><p dir="RTL">يمكن أن يتم زرع ميرينا خلال سبعة أيام من بداية النزف الحيضي. يمكن أن يتم زرع اللولب الهرموني مباشرة بعد الإجهاض الذي يحدث في الثلاثة شهور الأولى بشرط عدم وجود عدوى تناسلية.</p><p dir="RTL">لا يجب زرع اللولب الهرموني قبل عودة الرحم لحجمه الطبيعي على ان لا تقل هذه المدة عن 6 أسابيع من تاريخ الولادة (انظر الجزء 2 ثقب الرحم). يمكن استبدال ميرينا بميرينا جديد في أي وقت من الدورة.</p><p dir="RTL">عندما يستخدم ميرينا لحماية بطانة الرحم أثناء المعالجة بالإعاضة بالإستروجين، يمكن زرعه في أي وقت في امرأة ليس لديها نزف شهري (الحيض &ndash; الدورة الشهرية)، أو خلال الأيام الأخيرة من الحيض أو النزف الانسحابي.</p><p dir="RTL">يجب فقط أن تتم عملية إدخال (زرع) ميرينا من اطباء اخصائيين لديهم خبرة في إدخال (زرع) ميرينا أو حصلوا على تدريب كافٍ في إدخال (زرع) ميرينا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيف يتم إدخال ميرينا؟</strong></p><p dir="RTL">بعد القيام بالفحص النسائي، يتم إدخال أداة تسمى المنظار داخل المهبل، و يتم تنظيف عنق الرحم بسائل مطهر. ثم يتم زرع اللولب الهرموني عن طريق، أنبوب بلاستيك رقيق و مرن. يمكن استعمال مخدر موضعي لعنق الرحم للتخفيف من الألم، إذا كان ضرورياً.</p><p dir="RTL"><u>يمكن لبعض النساء أن تعاني من آلم و دوخة بعد الزرع. إذا لم تنتهي هذه الأعراض خلال نصف ساعة في وضع الاستراحة، ذلك يعني أن اللولب الهرموني ليس في الموضع السليم. يجب القيام بالفحص و إزالة اللولب الهرموني إذا كان ضروريا</u><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>متى يجب زيارة الطبيب؟</strong></p><p dir="RTL">يجب فحص اللولب الهرموني بعد 4 &ndash; 12 أسابيع من الإدخال (الزرع)، و بانتظام بعد ذلك، على الأقل مرة واحدة في السنة. طبيبك سوف يحدد عدد المرات وأي نوع من الفحوصات اللازمة على وجه التحديد في حالتك. إضافة لذلك، يجب الاتصال بطبيبك إذا حدث أي من الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لم تعودي تتحسسين الخيوط في المهبل باستخدام اصابعك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك الشعور بالنهاية السفلي للولب باستخدام الأصابع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تعتقدين باحتمال وجود حمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لديك آلم متواصل في البطن، ارتفاع لدرجة حرارة الجسم، أو إفرازات غير معتادة من المهبل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أنت أو زوجك تشعران بألم أو عدم ارتياح خلال الاتصال الجنسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تغيرات مفاجئة في دورات الطمث (على سبيل المثال، إذا حدث لك في البداية نزف حيضي قليل أو عدم وجود نزف حيضي، ثم بدء حدوث نزف متواصل أو آلم، أو بدء حدوث نزف كثيف).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل طبية أخرى، مثل صداع نصفي (الشقيقة) أو صداع شديد يتكرر، مشاكل مفاجئة بالرؤية، يرقان، أو ضغط دم مرتفع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا واجهتي أية من الحالات المذكورة في الجزء2. &laquo;قبل استخدام ميرينا&raquo;.</p><p dir="RTL">أخبري الطبيب المختص انه قد تم زرع ميرينا لك، خاصة إذا لم يكن هو من قام بزرعها لك</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما هي مدة استخدام ميرينا؟</strong></p><p dir="RTL">مدة فاعلية ميرينا 6 سنوات، عند استخدامه لمنع الحمل، ولمدة 5 سنوات عند استخدامه في حالات نزيف الحيض المفرط، وآلام الدورة الشهرية، وكعلاج بالبروجستيرون أثناء العلاج بالهرمونات البديلة لانقطاع الطمث. بعد هذه الفترة يجب إزالة اللولب الهرموني. إذا كنت ترغبين يمكن زرع لولب ميرينا جديد بعد إزالة القديم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ماذا لو أردت أن اصبح حاملا أو لإزالة ميرينا لسبب آخر؟</strong></p><p dir="RTL">يمكن إزالة اللولب الهرموني بسهولة في أي وقت بواسطة طبيبك، و بعدها يصبح الحمل ممكنا.</p><p dir="RTL">غالباً ما تكون الازالة غير مؤلمة. تعود الخصوبة لطبيعتها بعد إزالة ميرينا.</p><p dir="RTL">إذا كان الحمل غير مرغوب به، لا ينبغي إزالة ميرينا بعد اليوم السابع من الدورة الشهرية ما لم يتم التأكد من منع الحمل بأساليب أخرى (الواقي الذكري)، يبدأ استخدامها على الأقل سبعة أيام قبل الإزالة. إذا كانت الدورة لديك غير منتظمة أو منقطعة، يجب عليك استخدام أساليب الحاجز لمنع الحمل لمدة سبعة أيام قبل الإزالة و لحين حدوث الطمث. يمكن زرع ميرينا جديد فوراً بعد الإزالة، في هذه الحالة لا يوجد احتياج لوقاية إضافية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هل يمكن أن أصبح حاملا بعد التوقف عن استخدام ميرينا؟</strong></p><p dir="RTL">نعم. إزالة ميرينا لا يتداخل مع خصوبتك الطبيعية. يمكن أن تصبحين حامل خلال الدورة الحيضية الأولى بعد إزالة ميرينا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هل يمكن لميرينا أن يؤثر على دورات الحيض؟</strong></p><p dir="RTL">يؤثر ميرينا على دورتك الحيضية. يمكن أن يؤثر على دورات الحيض إلى حد أن يكون لديك تنقيط (كمية صغيرة من فقدان الدم)، فترات أقصر أو أطول، نزف أخف أو أثقل، أو عدم النزف مطلقاً.</p><p dir="RTL">نساء كثيرات لديهن تنقيط متكرر أو نزف خفيف بالإضافة لدوراتهن الحيضية في الثلاثة &ndash; ستة شهور الأولى بعد زرع ميرينا. بعض النساء يمكن أن يكون لديهن نزف ثقيل أو طويل المدة خلال هذا الوقت. الرجاء إبلاغ طبيبك إذا استمرت مثل هذه الأعراض.</p><p dir="RTL">إجمالياً، من المحتمل أن ينخفض تدريجياً عدد أيام النزف و كمية الدم المفقود كل شهر. في آخر الأمر بعض النساء تجدن أن الدورات الحيضية توقفت تماماً. بما أن كمية النزف الحيضي تنخفض تدريجياً أثناء استخدام ميرينا، فان معظم النساء تزداد لديهن قيم خضاب الدم (الهيموجلوبين).</p><p dir="RTL">عندما يتم إزالة اللولب، تعود الدورة الحيضية لحالتها الطبيعية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هل من غير الطبيعي عدم وجود دورات طمث؟</strong></p><p dir="RTL">ليس عندما يستخدم ميرينا. إذا وجدت أن ليس لديك دورات طمث مع ميرينا، يكون ذلك بسبب تأثير الهرمون على بطانة الرحم. لم تعد تحدث الزيادة الشهرية لسماكة بطانة الرحم. لذلك لن ينتج أي شيء كدورة طمث. هذا لا يعني بالضرورة بلوغ مرحلة انقطاع الطمث أو وجود حمل. تستمر مستويات هرموناتك طبيعية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيف سأعلم أنني حامل؟ </strong></p><p dir="RTL">الحمل بعيد الاحتمال في نساء تستخدمن ميرينا، حتى إذا لم يحدث لديهن دورات طمث.</p><p dir="RTL">إذا لم يحدث دورة الطمث لمدة ستة أسابيع و يوجد لديك قلق، إذاً يراعى القيام باختبار للحمل. إذا كانت نتيجة الاختبار سلبية، لا يوجد حاجة للقيام باختبار آخر إلا إذا كان لديك علامات أخرى للحمل، مثل غثيان، تعب أو ألم عند الضغط على الثدي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هل يمكن أن يسبب ميرينا ألم أو إزعاج؟</strong></p><p dir="RTL">بعض النساء تشعرن بألم (مثل مغص الطمث) في الأسابيع الأولى بعد الزرع. يجب مراجعة طبيبك إذا كان لديك ألم شديد أو اذا استمر الألم لأكثر من ثلاثة أسابيع بعد زرع ميرينا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هل يتداخل ميرينا مع الاتصال الجنسي؟</strong></p><p dir="RTL">من المفترض ألا تشعرين أنت أو شريكك بوجود اللولب الهرموني اثناء الاتصال الجنسي. إذا شعرتما بوجوده، يجب تجنب الاتصال الجنسي لحين تأكد الطبيب بأن اللولب الهرموني لا يزال في وضعه السليم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما هي المدة التي يجب أن أنتظرها قبل القيام بالإتصال الجنسي بعد زرع اللولب؟</strong></p><p dir="RTL">من أجل إعطاء جسمك فرصة للراحة، من الأفضل الإنتظار 24 ساعة بعد زرع ميرينا قبل القيام باتصال جنسي. مع ذلك، فور زرعه سوف يمنع ميرينا الحمل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هل يمكنني استخدام السدادات القطنية أو كأس الحيض؟</strong></p><p dir="RTL">يوصى باستخدام الفوط الصحية. إذا كنت تستخدمين السدادات القطنية أو كأس الحيض ، فيجب عليك تغييرها بعناية حتى لا تسحب خيوط ميرينا.</p><p dir="RTL">إذا كنت تعتقدين أنك ربما تكون قد سحبتي ميرينا من مكانها (انظري &laquo;متى يجب زيارة الطبيب&raquo; لمعرفة العلامات المحتملة) ، تجنبي الجماع أو استخدمي مانع حمل حاجز (مثل الواقي الذكري) ، واتصلي بطبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ماذا يحدث إذا خرج ميرينا من تلقاء نفسه؟</strong></p><p dir="RTL">من النادر و لكن ممكن لميرينا أن يخرج اثناء دورة الحيض بدون انتباه. إن حدوث زيادة غير عادية في كمية النزف اثناء دورة الحيض يمكن أن تعني أن ميرينا قد خرج من خلال المهبل. أيضاً من الممكن لجزء من ميرينا أن يخرج من الرحم (يمكن لك و لزوجك أن تلاحظا ذلك اثناء الاتصال الجنسي). إذا خرج ميرينا كاملاً أو جزئيا، سوف تكونين غير محمية من الحمل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيف يمكن أن اعرف أن ميرينا في موضعه؟</strong></p><p dir="RTL">يمكن القيام بالفحص بنفسك إذا كانت الخيوط في مكانها بعد دورة الحيض. ضعي برفق إصبع واحد داخل المهبل بعد دورة الحيض و تحسسي الخيوط عند نهاية المهبل قرب فتحة الرحم.</p><p dir="RTL"><strong>لا تسحبي الخيوط</strong> لأنه يمكن أن تسحبي ميرينا للخارج من غير قصد. إذا لم تتمكني من تحسس الخيوط، فهذا قد يشير إلى أن اللولب خرج من تلقاء نفسه أو أنه ثقب جدار الرحم. في هذه الحالة يجب استخدام وسيلة منع حمل حاجزة (مثل الواقي الذكري) واتصلي بطبيبك.</p><p dir="RTL">إذا كان لديك مزيد من الأسئلة عن استخدام هذا الدواء،، إسألي طبيبك او الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن لميرينا أن يسبب آثاراً جانبية، مع أن ليس كل شخص يصاب بهم.</p><p dir="RTL">بالإضافة للآثار الجانبية الممكنة التي تم ذكرها سابقاً في فقرات أخرى (مثل الفقرة 2. &laquo;ما الذي تحتاجين معرفته قبل استخدام ميرينا&raquo;)، هنا قائمة بالآثار الجانبية الممكنة التي تم تجميعها وفقاً للعضو الذي تم التأثير عليه، و تكرارها:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائع جداً </strong>(لدى أكثر من 1 في 10 من المرضى):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; نزف مهبلي / رحمي (يشمل بقع)، نزف غير منتظم (ندرة الطمث) و غياب النزف (انقطاع الحيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تضخم جريبات المبيض (أنظر الجزء 2 &laquo;تضخم جريبات المبيض&raquo;)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائع </strong>(لدى أكثر من 1 في 100 من المرضى):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مزاج مكتئب / كآبة عصبية، انخفاض الرغبة الجنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة، غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الحوض، عسر الطمث (حيض مؤلم)، إفرازات مهبلية، التهاب الفرج و المهبل (التهاب الاعضاء التناسلية الخارجية أو المهبل)، ألم الثدي، التألم عندما يتم الضغط على الثدي، طرد اللولب الهرموني</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائع </strong>(لدى أقل من 1 في 100 من المرضى):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الصداع النصفي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر، زيادة نمو شعر الجسم، حكة شديدة، إكزيما (التهاب الجلد)، بقع بلون الكبد على الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; مرض التهاب الحوض (عدوى الأعضاء التناسلية العلوية، أعلى عنق الرحم)، عدوى بطانة جدار الرحم، عدوى عنق الرحم مع وجود نتيجة طبيعية لفحص خلايا عنق الرحم، التصنيف II</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; وذمة (انتفاخ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; اختراق جدار الرحم</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادر </strong>(لدى أقل من 1 في 1000 من المرضى):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، الشرى (الاحمرار)</p><p dir="RTL">تم الإبلاغ عن حالات تعفن الدم (عدوى شديدة جداً تشمل الجسم بالكامل، التي قد تكون قاتلة) بعد إدخال اللولب الهرموني المانع للحمل.</p><p dir="RTL">إذا أصبحت حاملاً أثناء استخدام ميرينا، فمن المحتمل أن يكون الحمل خارج الرحم (انظري الجزء 2 &laquo;الحمل خارج الرحم&raquo;).</p><p dir="RTL">تم الإبلاغ ايضاً عن حالات سرطان الثدي (التكرار غير معروف).</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong><u>الإبلاغ عن الآثار الجانبية</u></strong></p><p dir="RTL">إذا تم إصابتك بأي آثار جانبية، تحدثي مع طبيبك، الصيدلي أو الممرضة. هذا يشمل أي آثار جانبية محتملة غير مذكورة في هذه النشرة. يمكن أن تساعد من خلال الإبلاغ عن الآثار الجانبية على توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong><strong>:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول أيدي و نظر الأطفال.</p><p dir="RTL">لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">لا يستخدم بعد تاريخ انتهاء المفعول المذكور على العبوة. يشير تاريخ انتهاء المفعول إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا يجب التخلص من الأدوية عن طريق الصرف الصحي أو النفايات المنزلية. اسألي الصيدلي كيف يتم التخلص من الأدوية التي لم تعد تستخدم. هذه التدابير سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي ميرينا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ليفونورجستريل. يحتوي كل لولب هرموني على 52 ميليغرام ليفونورجستريل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; المواد الأخرى هي كما يلي: اللب (النواة) هرمون &ndash; مطاط صناعي، (بولي داي ميثايل سيلوكسان و السيليكا)، جسم على شكل حرف تي (T) (بولي ايثيلين و كبريتات الباريوم)، خيط السحب (بولي ايثيلين و اوكسيد الحديد (E172)).</p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:13.0pt; text-align:right; text-indent:-14.2pt"><!--[if !supportLists]--></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو ميرينا و ما هي محتويات العبوة</strong></p><p dir="RTL">حجم العبوة: عبوة تحتوي على لولب هرموني واحد معقم.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الحاصل على حق التسويق</strong></p><p dir="RTL">باير أو واى</p><p dir="RTL">توركو، فنلندا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المصنع</strong></p><p dir="RTL">باير أو واى</p><p dir="RTL">47 شارع بانسيونتيه</p><p dir="RTL">20210 توركو &ndash; فنلندا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mirena 20 micrograms/24 hours intrauterine delivery system
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One intrauterine delivery system contains 52 mg of levonorgestrel. The average in vivo release rate is approximately 20 micrograms per 24 hours during the first year.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Intrauterine delivery system (IUS)

The IUS consists of a white or almost white hormone-elastomer core covered with an opaque membrane, which is mounted on the vertical stem of a T-body. The white T-body has a loop at one end and two horizontal arms at the other end. Two brown removal threads are attached to the loop. The T-frame of Mirena contains barium sulphate, which makes it visible in X-ray examination. The vertical stem of the IUS is inside the insertion tube. The IUS is free of impurities.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contraception, idiopathic menorrhagia/hypermenorrhea, dysmenorrhea, and local progestogen treatment during estrogen replacement therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mirena is inserted into the uterine cavity. It is effective for 8 years in the indication of contraception and 5 years in the indications of idiopathic menorrhagia/hypermenorrhea, dysmenorrhea, and local progestogen treatment during estrogen replacement therapy. For timing regarding removal/replacement, see section Removal/replacement.</p><p>&nbsp;</p><p>Mirena should only be inserted by healthcare professionals who are experienced in Mirena insertions or have undergone sufficient training for Mirena insertion.</p><p>&nbsp;</p><p><u>Insertion</u></p><p><u>&nbsp;</u></p><p><em>Mirena as a contraceptive</em></p><p><u>&nbsp;</u></p><p>Mirena is inserted into the uterine cavity during menstrual bleeding, within seven days of the onset of menstruation. Mirena can be replaced by a new system at any time in the cycle. Mirena can also be inserted in connection with abortion.</p><p>Postpartum insertions should be postponed until the uterus is fully involuted, however not earlier than six weeks after delivery. If involution is delayed, the recommendation is to wait until 12 weeks postpartum. In case of a difficult insertion or exceptional pain or bleeding during or after insertion, the possibility of perforation of the uterine wall should be considered and excluded by taking appropriate steps, such as pelvic examination and ultrasound. A pelvic examination alone (including checking of threads) may not be sufficient to exclude partial perforation of the uterine wall.</p><p>&nbsp;</p><p>Mirena is not intended for use as a postcoital contraceptive.</p><p>&nbsp;</p><p><em>Mirena in the treatment of idiopathic menorrhagia/hypermenorrhea and dysmenorrhea</em></p><p><u>&nbsp;</u></p><p>Mirena is inserted into the uterine cavity during menstrual bleeding, within seven days of the onset of menstruation. Mirena can be replaced by a new system at any time in the cycle.</p><p>&nbsp;</p><p><em>Mirena as local progestogen treatment during estrogen replacement therapy</em></p><p><u>&nbsp;</u></p><p>In women using Mirena as part of their hormone replacement therapy, it can be used in combination with oral or transdermal estrogen therapy. Because spotting is common during the first months of therapy, a sample should be taken from the uterine cavity to check the endometrium before insertion of Mirena. If the woman continues the use of Mirena as part of hormone replacement therapy when there is no longer need for contraception, an endometrial sample has to be taken in case bleeding appears after commencing estrogen therapy or develops later during therapy. Mirena can be inserted at any time in amenorrheic women, or during menstruation or withdrawal bleeding if they still occur.</p><p>&nbsp;</p><p>In the treatment of menorrhagia and in local progestogen treatment in conjunction with estrogen replacement therapy Mirena releases a sufficient amount of levonorgestrel during a five-year period to prevent proliferation of the endometrium. When Mirena is replaced with a new system, it can be inserted immediately into the uterine cavity.</p><p>&nbsp;</p><p><u>Removal/replacement</u></p><p><em><u>&nbsp;</u></em></p><p><em>Contraception: </em>When used for contraception, Mirena must be removed or replaced with a new system after eight years. If pregnancy is not desired, the removal should be carried out within seven days of the onset of menstruation in women of fertile age, provided that the woman is still experiencing regular menses. If the system is removed at some other time during the cycle or the woman does not experience regular menses and the patient has had intercourse within a week prior to removal, she is at risk of pregnancy. To ensure continuous contraception a new system should be immediately inserted, or an alternative contraceptive method should be initiated.</p><p><em>&nbsp;</em></p><p><em>Idiopathic menorrhagia/hypermenorrhea:</em> Mirena must be removed or replaced with a new system in case symptoms of idiopathic menorrhagia/hypermenorrhea return. If symptoms have not returned after five years of use, continued use of the system may be considered. Remove or replace Mirena eight years after insertion at the latest.</p><p>&nbsp;</p><p><em>Dysmenorrhea and local progestin treatment in conjunction with estrogen replacement therapy: </em>Mirena must be removed or replaced with a new system after five years.</p><p>&nbsp;</p><p>Mirena is removed by gently pulling on the threads with forceps. The use of excessive force or sharp instruments during removal may cause breakage of the device. After removal of Mirena, the system should therefore be examined to ensure that it has been removed entirely. During difficult removals, single cases have been reported of the hormone cylinder sliding over the horizontal arms and hiding them together inside the cylinder. This situation does not require further intervention once the removed IUS has been ascertained to be otherwise intact. The knobs at the end of the horizontal arms usually prevent complete detachment of the hormone cylinder from the T-body. If the threads are not visible and the system is in the uterine cavity, it may be removed using a narrow tenaculum. This may occasionally require dilatation of the cervical canal or other measures. Insertion and removal may be associated with short-term pain and bleeding. The procedure may precipitate a vasovagal reaction or a seizure in an epileptic patient.</p><p>&nbsp;</p><p>If the user wishes to continue using the same method, a new system can be inserted at the time of removal.</p><p><u>&nbsp;</u></p><p><u>Instructions for handling and use</u></p><p><u>&nbsp;</u></p><p>Mirena is supplied in a sterile pack which should not be opened until required for insertion. Each product should be handled with aseptic precautions. If the seam of the package is broken, the product cannot be used.</p><p>&nbsp;</p><p>Mirena is supplied with a patient reminder card in the outer carton. Complete the patient reminder card and give it to the patient after insertion.</p><p>&nbsp;</p><p><u>Pediatric population</u></p><p><u>&nbsp;</u></p><p>There is no relevant indication for the use of Mirena before menarche.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Known or suspected pregnancy 
•	Progestogen-dependent tumors, e.g. breast cancer
•	Acute or recurrent pelvic inflammatory disease
•	Cervicitis
•	Lower genital tract infection
•	Postpartum endometritis
•	Infected miscarriage or abortion during the past three months
•	Increased susceptibility to infections
•	Cervical dysplasia
•	Confirmed or suspected uterine or cervical malignancies
•	Undiagnosed abnormal uterine bleeding
•	Congenital or acquired uterine anomaly, including fibroids if they distort the uterine cavity
•	Acute liver disease or liver tumor
Hypersensitivity to the active substance or to any of the excipients.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mirena may be used with caution after specialist consultation, or removal of the system should be considered if any of the following conditions arise for the first time:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Migraine, focal migraine with asymmetrical visual loss, or other symptoms indicating transient cerebral ischemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exceptionally severe headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Marked increase in blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe arterial disease such as cerebrovascular accident or myocardial infarction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute venous thromboembolism.</p><p>&nbsp;</p><p>Appropriate diagnostic and therapeutic measures should be undertaken immediately if there are symptoms indicating retinal thrombosis, such as unexplained partial or complete loss of vision, proptosis or diplopia, papilledema, or retinal vascular lesions.</p><p>&nbsp;</p><p>There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in thromboembolism. Mirena may be used with caution in women who have congenital heart disease or valvular heart disease and are at risk of contracting infectious endocarditis.&nbsp;</p><p>&nbsp;</p><p>Low-dose levonorgestrel may affect glucose tolerance, and the blood glucose concentration should be monitored in diabetic users of Mirena. However, there is usually no need to adjust the treatment in diabetic users of Mirena.</p><p>&nbsp;</p><p>Irregular bleedings may mask symptoms of cervical or endometrial polyps or cancer, and in these cases diagnostic measures have to be considered.</p><p>&nbsp;</p><p>Mirena is not the method of first choice for postmenopausal women with advanced uterine atrophy.</p><p>&nbsp;</p><p>When Mirena is used concomitantly with estrogen in hormone replacement therapy, the safety data relevant to estrogens should also be considered.</p><p>&nbsp;</p><p><u>Medical examination and precautions</u></p><p>&nbsp;</p><p>Before insertion, the woman must be informed of the efficacy, risks (including the signs and symptoms of risks described in the package leaflet) and adverse effects of Mirena. A pelvic examination, examination of the breasts, and a cervical smear if not taken within three months, should be performed before insertion. Pregnancy and sexually transmitted diseases should be excluded. Genital infections have to be successfully treated prior to insertion. The position of the uterus and the size of the uterine cavity should be determined. Fundal positioning of Mirena is important in order to ensure uniform exposure of the uterus to the progestogen. The risk of expulsion will then also be low and the contraceptive efficacy is maximized. It is important that the instructions for insertion are followed carefully. Since the insertion technique of Mirena is different from other intrauterine devices, special emphasis should be given to training in the correct insertion technique. Insertion and removal may be associated with short-term pain and bleeding. The procedure may precipitate fainting as a vasovagal reaction, or a seizure in an epileptic patient. If an insertion is expected to be associated with problems and/or severe pain, use of a system with an insertion tube with a smaller diameter should be considered.</p><p>&nbsp;</p><p>The woman should be re-examined 4 to 12 weeks after insertion and once a year thereafter, or when clinically indicated.</p><p>&nbsp;</p><p>Mirena is not suitable for use as a post-coital contraceptive.</p><p>&nbsp;</p><p>Since irregular bleeding and spotting are common during the first months of therapy, endometrial pathology should be excluded before the insertion of Mirena. If the woman continues the use of Mirena as part of hormone replacement therapy when there is no longer need for contraception, required diagnostic measures have to be taken in case bleeding appears after commencing estrogen replacement therapy. If bleeding irregularities develop during a prolonged treatment, appropriate diagnostic measures should also be taken.</p><p>&nbsp;</p><p><u>Oligomenorrhea and amenorrhea</u></p><p>&nbsp;</p><p>In women of fertile age, oligomenorrhea and amenorrhea develop gradually in about 57% and 16% of women, respectively, during the first year of use. By the end of year 8 of Mirena use, oligomenorrhea and amenorrhea are experienced by 26% and 34% of Mirena users, respectively. The possibility of pregnancy should be excluded if menstruation does not occur within six weeks of the onset of the previous menstruation, and a check should be made to ensure that the system is still in place. A repeated pregnancy test is not necessary in patients who remain amenorrheic unless indicated by other signs of pregnancy.</p><p>&nbsp;</p><p>Due to the strong local effect levonorgestrel has on the endometrium, the endometrial lining does not react to estrogen and, therefore, proliferation does not occur. The duration and volume of menstrual bleeding is reduced. When women with different bleeding patterns were compared, no clear difference in follicle development, ovulation or estradiol or progesterone production was found. In menorrhagic women, the volume of menstrual bleeding decreased by 62&ndash;94% during the first three months of use and 71&ndash;95% during the first six months of use. Reduced bleeding increases the hemoglobin level. When local progestogen treatment is used in combination with estrogen therapy, amenorrhea gradually develops in most women during the first year. Irregular bleeding and spotting were fairly common during the first three months of use.</p><p>&nbsp;</p><p><u>Pelvic infections</u></p><p>&nbsp;</p><p>The insertion tube helps to protect Mirena from contamination with micro-organisms during the insertion, and the inserter has been designed to minimize the risk of infections. Based on the experience obtained from users of copper intrauterine devices, the risk of infection is highest during the first month of use and decreases later. The risk of infection is highest in young women or if the woman or her partner have multiple sexual partners. A pelvic inflammatory disease may have serious consequences and it may impair fertility and increase the risk of ectopic pregnancy. As with other gynecological or surgical procedures, severe infection or sepsis (including group A streptococcal sepsis) can occur following IUD insertion, although this is extremely rare.</p><p>&nbsp;</p><p>If an acute infection does not respond to treatment within a few days, or if the patient experiences recurrent endometritis or other pelvic infections, Mirena must be removed (see section 4.3). Some studies indicate that the rate of pelvic infections in users of Mirena is lower than in users of copper-releasing intrauterine devices.</p><p>&nbsp;</p><p>Bacteriological examinations are indicated and monitoring is recommended, even with discrete symptoms indicative of infections.</p><p>&nbsp;</p><p><u>Expulsion</u></p><p>&nbsp;</p><p>In clinical trials with Mirena in the contraception indication, the incidence of expulsion was low (&lt;4% of insertions) and in the same range as reported for other IUDs and IUSs.</p><p>Symptoms of partial or complete expulsion of Mirena may include bleeding or pain. However, the system can be expelled from the uterine cavity without the woman noticing it, leading to loss of contraceptive protection. As Mirena normally decreases menstrual flow, an increase in menstrual flow may be indicative of an expulsion.</p><p>&nbsp;</p><p>The risk of expulsion is increased in</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; women with history of heavy menstrual bleeding (including women who use Mirena for the treatment of heavy menstrual bleeding)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; women with a higher than normal BMI at the time of insertion; this risk increases gradually with increasing BMI.</p><p>&nbsp;</p><p>Women should be counselled on possible symptoms of expulsion and how to check the threads of Mirena and advised to contact a healthcare professional if the threads cannot be felt. A barrier contraceptive (such as a condom) should be used until the location of Mirena has been confirmed.</p><p>&nbsp;</p><p>Partial expulsion may decrease the effectiveness of Mirena.</p><p>A partially expelled Mirena should be removed. A new system can be inserted at the time of removal, provided pregnancy has been excluded.</p><p>&nbsp;</p><p><u>Perforation</u></p><p>&nbsp;</p><p>Perforation or penetration of the uterine corpus or cervix by an intrauterine contraceptive may occur, most often during insertion, and it may not be detected until later. A system located outside the uterus has reduced contraceptive efficacy: Such a system must be removed. Surgery may be required.</p><p>&nbsp;</p><p>In a large prospective non-interventional cohort study in users of intrauterine contraceptive (n = 61,448 women), the incidence of perforation during a 1-year observational period was 1.3 (95% CI: 1.1&ndash;1.6) per 1000 insertions in the entire study cohort, 1.4&nbsp;(95% CI: 1.1&ndash;1.8) per 1000 insertions in the Mirena cohort, and 1.1&nbsp;(95% CI: 0.7&ndash;1.6) per 1000 insertions in the copper IUD cohort.</p><p>&nbsp;</p><p>The study showed that insertion was associated with an increased risk of perforation both during breastfeeding and up to 36 weeks after giving birth (see Table 1). Both of these risk factors were independent of the type of intrauterine contraceptive inserted.</p><p>&nbsp;</p><p>Table 1: Incidence of perforation per 1000 insertions for the entire study cohort observed over 1 year, stratified by breastfeeding and time since delivery at insertion</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Breastfeeding at time of insertion</p></td><td style="vertical-align:top"><p>Not breastfeeding at time of insertion</p></td></tr><tr><td style="vertical-align:top"><p>Insertion &le; 36 weeks after delivery</p></td><td style="vertical-align:top"><p>5.6</p><p>(95% CI 3.9&ndash;7.9; n&nbsp;=&nbsp;6,047&nbsp;insertions)</p></td><td style="vertical-align:top"><p>1.7</p><p>(95% CI 0.8&ndash;3.1; n&nbsp;=&nbsp;5,927&nbsp;insertions)</p></td></tr><tr><td style="vertical-align:top"><p>Insertion &gt; 36 weeks after delivery</p></td><td style="vertical-align:top"><p>1.6</p><p>(95% CI 0.0&ndash;9.1; n&nbsp;=&nbsp;608&nbsp;insertions)</p></td><td style="vertical-align:top"><p>0.7</p><p>(95% CI 0.5&ndash;1.1; n&nbsp;=&nbsp;41,910&nbsp;insertions)</p></td></tr></tbody></table><p>&nbsp;</p><p>When the observational period was extended to 5 years in a subgroup of this study (n = 39,009 women using Mirena or copper IUD; for 73% of these women the data were available for the entire observational period), the incidence of perforation detected at any time during the 5-year period was 2.0 (95% CI: 1.6&ndash;2.5) per 1000 insertions. Insertion during breastfeeding and up to 36 weeks after giving birth were confirmed as risk factors also in the subgroup followed up for 5 years.</p><p>&nbsp;</p><p>The risk of perforation may be increased in women with fixed retroverted uterus.&nbsp;</p><p>&nbsp;</p><p>Re-examination after insertion should follow the guidance given under the heading &quot;Medical examination and precautions&quot;. The guidance may be adapted as clinically indicated in women with risk factors for perforation.</p><p><u>&nbsp;</u></p><p><u>Breast cancer</u></p><p>&nbsp;</p><p>A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using combined oral contraceptives (COCs), mainly estrogen-progestogen preparations. The excess risk gradually disappears during the course of 10 years after cessation of COC use. Since breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer. The risk of having breast cancer diagnosed in users of progestogen-only oral contraceptives (OCs) is possibly of similar magnitude to that associated with COCs. However, for progestogen-only preparations, the evidence is based on much smaller populations of users and is so less conclusive than that for COCs. These studies do not provide evidence for causality. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in OC users, the biological effects of OCs or a combination of both. The breast cancers diagnosed in women using COCs continuously tend to be less advanced clinically than the cancers diagnosed in women who have never used COCs.</p><p>&nbsp;</p><p>The risk of breast cancer is increased in menopausal women using systemic hormone replacement therapy (tablets or a preparation applied on the skin). The risk is higher in users of the combination of estrogen and progestogen than in users of estrogen only. The product information on the estrogen preparation used in the treatment must also be read through.</p><p>&nbsp;</p><p><u>Ectopic pregnancy</u></p><p>&nbsp;</p><p>The possibility of ectopic pregnancy should be considered in case of lower abdominal pain &ndash; especially in connection with missed periods or if an amenorrheic woman starts bleeding. Women with a previous history of ectopic pregnancy, tubal surgery or pelvic infection carry a higher risk of ectopic pregnancy. The absolute risk of ectopic pregnancy in Mirena users is lower since the total likelihood of pregnancy is lower in Mirena users compared with women not using any contraception. In a large prospective non-interventional cohort study with an observational period of 1 year, the ectopic pregnancy rate with Mirena was 0.02%. In clinical trials, the absolute incidence of ectopic pregnancies with Mirena was approximately 0.1% per year. This rate is lower than the rate in women not using any contraception (0.3&ndash;0.5% per year). However, if a woman becomes pregnant with Mirena in situ, the risk of ectopic pregnancy is increased.</p><p>&nbsp;</p><p><u>Retrieval threads</u></p><p>&nbsp;</p><p>If the retrieval threads are not visible at the cervix, pregnancy must be excluded. The threads may have been drawn up into the uterus or cervical canal and may reappear during the next menstrual period. If pregnancy has been excluded, the threads may usually be retrieved from the cervical canal with a suitable instrument. If they cannot be found, the possibility of expulsion or perforation should be considered. Ultrasound examination may be used to ascertain the position of the system. If ultrasound is not available or successful, X-ray may be used to locate Mirena.</p><p>&nbsp;</p><p><u>Ovarian cysts</u></p><p>&nbsp;</p><p>Since Mirena has a mainly local mechanism of action, ovulatory cycles with follicular rupture usually occur normally in women of fertile age. Sometimes atresia of the follicle is delayed and folliculogenesis may continue. These enlarged follicles cannot be distinguished clinically from ovarian cysts. Ovarian cysts have been reported as adverse drug reactions in approximately 7% of the women using Mirena. Most of these cysts are asymptomatic, although some may be accompanied by pelvic pain or dyspareunia.</p><p>&nbsp;</p><p>In most cases, the ovarian cysts disappear spontaneously during 2 to 3 months. Should this not happen, ultrasound monitoring and other diagnostic/therapeutic measures based on the findings are recommended. Surgical intervention is required rarely.</p><p>&nbsp;</p><p><u>Psychiatric disorders</u></p><p>&nbsp;</p><p>Depressed mood and depression are well-known undesirable effects of hormonal contraceptive use (see section 4.8). Depression can be serious and is a well-known risk factor for suicidal behavior and suicide. Women should be advised to contact their physician in case of mood changes and depressive symptoms, including shortly after initiating the treatment.</p><p>&nbsp;</p><p><u>Precautions at time of removal</u></p><p>The use of excessive force or sharp instruments during removal may cause breakage of the device (see section 4.2). After removal of Mirena, the system should therefore be examined to ensure that it has been removed entirely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions can occur with drugs that induce liver enzymes, which can result in increased clearance of sex hormones.</p><p>&nbsp;</p><p><em>Substances increasing the clearance of levonorgestrel, e.g.:</em></p><p>&nbsp;</p><p>Phenytoin, barbiturates, primidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin, and herbal preparations containing St. John&#39;s wort (<em>Hypericum perforatum</em>).</p><p>&nbsp;</p><p>The influence of these drugs on the contraceptive efficacy of Mirena is not known, but it is not believed to be of major importance due to the local mechanism of action.</p><p>&nbsp;</p><p><em>Substances with variable effects on the clearance of levonorgestrel, e.g.:</em></p><p>&nbsp;</p><p>When co-administered with sex hormones, many anti-HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors can increase or decrease plasma concentrations of the progestin.</p><p>&nbsp;</p><p><em>Substances decreasing the clearance of levonorgestrel (enzyme inhibitors):</em></p><p>&nbsp;</p><p>Strong and moderate CYP3A4 inhibitors such as azole antifungals (e.g. fluconazole, itraconazole, ketoconazole, voriconazole), verapamil, macrolides (e.g. clarithromycin, erythromycin), diltiazem and grapefruit juice can increase plasma concentrations of the progestin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>The use of Mirena during an existing or suspected pregnancy is contraindicated, see section 4.3 Contraindications. If the woman becomes pregnant when using Mirena, the system should be removed as soon as possible, since any intrauterine contraceptive left in situ may increase the risk of abortion and preterm labor. Removal of Mirena may also result in spontaneous abortion. Ectopic pregnancy should be excluded. If the woman wishes to continue the pregnancy and the system cannot be withdrawn, she should be informed about the risks and the possible consequences of premature birth to the infant. The course of such a pregnancy should be closely monitored. The woman should be instructed to report all symptoms that suggest complications of the pregnancy, such as cramping abdominal pain with fever.</p><p>&nbsp;</p><p>In addition, an increased risk of virilizing effects in a female fetus because of the intrauterine exposure to levonorgestrel cannot be excluded. There have been isolated cases of masculinization of the external genitalia of the female fetus following local exposure to levonorgestrel during pregnancy with a hormonal IUS in place.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>&nbsp;</p><p>The daily dose and the plasma concentrations of levonorgestrel are lower with Mirena than with any other hormonal contraceptive method but levonorgestrel has been identified in breast milk. About 0.1% of the levonorgestrel dose is transferred to the infant during breastfeeding. Hormonal contraceptives are not recommended as the method of first choice during lactation, but progestogen-only methods are considered the second choice after non-hormonal contraceptive methods. There appears to be no deleterious effects on infant growth or development when using any progestogen-only method after six weeks postpartum. Progestogen-only methods do not appear to affect the quantity or quality of breast milk.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Upon removal of Mirena, women return to their normal fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Subjective undesirable effects may occur during the first months after insertion but they usually subside during prolonged use. In addition to the adverse effects listed in section 4.4, the following undesirable effects have been reported in users of Mirena.</p><p>&nbsp;</p><p>Very common undesirable effects (occurring in more than 10% of users) include uterine/vaginal bleeding (including spotting), oligomenorrhea, amenorrhea, and benign enlarged follicles.</p><p>&nbsp;</p><p>In women of fertile age, the number of spotting days per month decreases gradually from nine to four during the first six months of use. After the first month of use, 20% of users experience prolonged bleeding (more than eight days). For many women, periods become shorter after this, and after three months of use only 3% of users experience prolonged bleeding. In clinical trials during the first year of use, 17% of women experienced amenorrhea for a period of at least three months. By the end of year 8 of Mirena use, prolonged bleeding and irregular bleeding are experienced by 3% and 10% of Mirena users, respectively; amenorrhea occurs in 34%, and infrequent bleeding in 26% of Mirena users.</p><p>&nbsp;</p><p>When Mirena is used as local progestogen therapy in combination with estrogen replacement therapy, most women experience spotting or irregular bleeding during the first months of the treatment. Bleeding and spotting decrease gradually, and in about 40% of the users the periods stop completely within the last three months of the first year of use. Bleeding disorders were more common in perimenopausal women than in postmenopausal women.</p><p>&nbsp;</p><p>The frequency of benign ovarian cysts depends on the diagnostic method used, and they have been diagnosed in 7% of the users as adverse effects. Most of the follicles are asymptomatic and disappear spontaneously within three months.</p><p>&nbsp;</p><p>Table 2 below presents a summary of adverse reactions by MedDRA system organ classes. The frequencies are based on clinical trial data.</p><p>&nbsp;</p><p>Table 2: Adverse drug reactions</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><thead><tr><td style="vertical-align:top">&nbsp;<p>System Organ Class</p></td><td style="vertical-align:top"><p>Very common<br />(&ge; 1/10)</p></td><td style="vertical-align:top"><p>Common<br />(&ge; 1/100 to &lt; 1/10)</p></td><td style="vertical-align:top"><p>Uncommon (&ge; 1/1,000 to &lt; 1/100)</p></td><td style="vertical-align:top"><p>Rare<br />(&ge; 1/10,000 to &lt; 1/1,000)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depressed mood/<br />depression<br />Nervousness<br />Decreased libido</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Migraine</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abdominal pain<br />Nausea</p></td><td style="vertical-align:top"><p>Abdominal distension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Acne</p></td><td style="vertical-align:top"><p>Alopecia<br />Hirsutism<br />Pruritus<br />Eczema<br />Chloasma/skin hyperpigmentation</p></td><td style="vertical-align:top"><p>Rash<br />Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Benign ovarian cysts<br />Uterine/vaginal bleeding, including spotting, oligomenorrhea, amenorrhea</p></td><td style="vertical-align:top"><p>Pelvic pain<br />Dysmenorrhea<br />Vaginal discharge<br />Vulvovaginitis<br />Breast tenderness<br />Breast pain<br />Expulsion of the intrauterine contraceptive</p></td><td style="vertical-align:top"><p>Uterine perforation*</p><p>Pelvic inflammatory disease<br />Endometritis<br />Cervicitis / Pap smear normal, class II</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Edema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Weight increase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>The most appropriate MedDRA term is used to describe a certain adverse reaction and its synonyms and related conditions.</p><p>&nbsp;</p><p>* This frequency is based on a large prospective non-interventional cohort study which showed that breastfeeding at the time of insertion and insertion up to 36 weeks after giving birth are independent risk factors for perforation (see section 4.4). The frequency of perforation was &quot;rare&quot; in clinical trials with Mirena that excluded breastfeeding women.</p><p>&nbsp;</p><p>A separate study with 362 women who have used Mirena for more than 5 years showed a consistent adverse reaction profile in years 6 through 8.</p><p>&nbsp;</p><p>Infections:</p><p>Cases of sepsis (including group A streptococcal sepsis) have been reported following insertion of intrauterine contraceptives (see section 4.4).</p><p>&nbsp;</p><p>Pregnancy, puerperium and perinatal conditions:</p><p>If a woman becomes pregnant with the IUS in situ, the relative risk of ectopic pregnancy is increased (see section 4.4).</p><p>&nbsp;</p><p>Reproductive system and breasts:</p><p>Cases of breast cancer have also been reported in connection with the use of the IUS (frequency unknown; see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to:</p><p>&nbsp;</p><p><strong>Saudi Arabia</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Plastic IUD with progestogen</p><p><strong>ATC code:</strong> G02BA03</p><p>&nbsp;</p><p>Levonorgestrel is a progestogen with antiestrogenic activity used in gynecology in various ways: as the progestogen component in hormonal therapy and in combined oral contraceptives and alone in the so-called &#39;minipills&#39; and subdermal implants. Mirena releases levonorgestrel directly into the uterus. This allows a very low daily dosage, as the hormone is released directly into the target organ. The plasma concentrations of levonorgestrel are thus lower than with any other contraceptive method.</p><p>&nbsp;</p><p>Mirena has mainly local progestogenic effects in the uterine cavity. The high levonorgestrel concentrations in the endometrium prevent the synthesis of endometrial estrogen and progesterone receptors, making the endometrium insensitive to estrogen and producing an antiproliferative effect. Morphological changes of the endometrium and a weak local foreign body reaction are observed during the use of Mirena. Thickening of the cervical mucus prevents passage of the sperm through the cervical canal. In addition, the local milieu of the uterus and the ovarian tubes strongly inhibits sperm mobility and function, preventing fertilization. Ovulation is inhibited in some women.</p><p>&nbsp;</p><p>The contraceptive efficacy of Mirena has been studied in five major clinical studies with 3,330 women using Mirena. The contraceptive efficacy of Mirena beyond 5 years has been studied in 362 women in a clinical trial using Mirena, with 221 women completing year 8 of the study. During years 6 to 8 of Mirena use, the Pearl Index was 0.28 [95% CI (0.03; 1.00)]. The contraceptive efficacy of Mirena is summarized in Table 3.</p><p>&nbsp;</p><p>Table 3: Cumulative failure rate (%) and Pearl Index</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong>Year</strong></p></td><td style="vertical-align:top"><p><strong>Cumulative failure rate (%)*</strong></p><p><strong>(95% confidence interval)</strong></p></td><td style="vertical-align:top"><p><strong>Pearl Index</strong></p><p><strong>(95% confidence interval)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Contraceptive efficacy during Years 1 to 5 </strong></p><p>(N= 3,330, Pooled data of contraceptive trials up to five years)</p></td></tr><tr><td style="vertical-align:top"><p>Year 1</p></td><td style="vertical-align:top"><p>0.20 (0.09; 0.46)</p></td><td style="vertical-align:top"><p>0.21 (0.08; 0.45)</p></td></tr><tr><td style="vertical-align:top"><p>Years 1 to 5</p></td><td style="vertical-align:top"><p>0.71 (0.37; 1.33)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Contraceptive efficacy during Years 6 to 8 </strong></p><p>(N=362, Mirena Extension Trial)</p></td></tr><tr><td style="vertical-align:top"><p>Year 6</p></td><td style="vertical-align:top"><p>0.29 (0.04; 2.05)</p></td><td style="vertical-align:top"><p>0.34 (0.01; 1.88)</p></td></tr><tr><td style="vertical-align:top"><p>Year 7</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.40 (0.01; 2.25)</p></td></tr><tr><td style="vertical-align:top"><p>Year 8</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.00 (0.00; 1.90)</p></td></tr><tr><td style="vertical-align:top"><p>Years 6 to 8</p></td><td style="vertical-align:top"><p>0.68 (0.17; 2.71)</p></td><td style="vertical-align:top"><p>0.28 (0.03; 1.00)</p></td></tr></tbody></table><p>* Kaplan-Meier method</p><p>&nbsp;</p><p>The failure rate also includes pregnancies occurring after undetected expulsions and perforations. Similar contraceptive efficacy has been observed in a large post-marketing study with 17,000 women using Mirena. Because the use of Mirena does not require daily intake compliance, the pregnancy rates in &quot;typical use&quot; are similar to those observed in controlled clinical trials (perfect use).</p><p>&nbsp;</p><p>When toleration is measured by continuation rate, the Mirena method has been as well tolerated in contraceptive use as copper intrauterine devices. The continuation rate after the first year of use is approximately 80%.</p><p>&nbsp;</p><p>The use of Mirena does not alter the course of future fertility. After removal of the system, fertility returns to the same level as in women using no contraception. About 80% of the women who had their Mirena removed because they wished to become pregnant conceived within 12 months after the removal.</p><p>&nbsp;</p><p>The menstrual pattern is a result of the direct action of levonorgestrel on the endometrium, and it is not regulated by the ovarian function. There is no difference in follicle development, ovulation or estradiol and progesterone production in women with different bleeding patterns. In the process of inactivation of the proliferation of the endometrium, there can be an initial increase in spotting during the first months of use. Thereafter, the strong suppression of the endometrium results in reduction of the duration and volume of menstrual bleeding during the use of Mirena. Scanty flow frequently develops into oligomenorrhea or amenorrhea. Ovarian function is normal and estradiol levels are maintained, even when users of Mirena are amenorrheic.</p><p>&nbsp;</p><p>Mirena has been developed especially for women requiring long-term, effective contraception. It can also be successfully used in the treatment of menorrhagia. In menorrhagic women, the volume of menstrual bleeding decreases by 62&ndash;94% during the first three months of use and 71&ndash;95% during six months of use. Compared to endometrial ablation or resection, Mirena is equally effective in reducing the menstrual blood loss for up to two years. Reduced bleeding increases the hemoglobin level. Menorrhagia caused by submucosal fibroids may respond less favorably. Like oral contraceptives, Mirena also alleviates dysmenorrhea.</p><p>&nbsp;</p><p>The effect of Mirena in the treatment of menorrhagia and in local progestogen treatment in conjunction with estrogen replacement therapy is based on the action levonorgestrel exerts on the endometrium, preventing endometrial proliferation. No endometrial hyperplasias were reported during a 12-month study. Similar prevention of proliferation has been achieved in patients using estrogen orally, transdermally or subcutaneously. The amount of levonorgestrel released by Mirena is sufficient to prevent endometrial proliferation for five years.</p><p>&nbsp;</p><p>Mirena has been equally effective in preventing endometrial hyperplasia as estrogen used either orally or transdermally. The observed frequency of hyperplasia during estrogen-only therapy has been up to 20%. In clinical trials with a total of 634 perimenopausal and postmenopausal users of Mirena, no hyperplasia was reported during the observation period ranging from one to five years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levonorgestrel is released locally into the uterine cavity. Estimated <em>in vivo</em> release rates for different time points are provided in Table 4.</p><p><strong>&nbsp;</strong></p><p>Table 4: Estimated <em>in vivo </em>release rates for Mirena:</p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td><p>Time</p></td><td><p>Estimated <em>in vivo</em> release rate<br />[microg/24 hours]</p></td></tr><tr><td><p>24 days after insertion</p></td><td><p>21</p></td></tr><tr><td><p>60 days after insertion</p></td><td><p>21</p></td></tr><tr><td><p>1 year after insertion</p></td><td><p>19</p></td></tr><tr><td><p>3 years after insertion</p></td><td><p>14</p></td></tr><tr><td><p>5 years after insertion</p></td><td><p>11</p></td></tr><tr><td><p>8 years after insertion</p></td><td><p>7</p></td></tr><tr><td><p>Average over 1 years</p></td><td><p>20</p></td></tr><tr><td><p>Average over 3 years</p></td><td><p>18</p></td></tr><tr><td><p>Average over 5 years</p></td><td><p>15</p></td></tr><tr><td><p>Average over 8 years</p></td><td><p>13</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Following insertion, levonorgestrel is released into the uterine cavity without delay based on serum concentration measurements.&nbsp; The released levonorgestrel is fully systemically available.</p><p>&nbsp;</p><p>After insertion of Mirena, levonorgestrel is detectable in serum/plasma after 1 hour. The maximum concentration of 180 ng/l (coefficient of variation, CV 38.3%). is reached within 2 weeks after insertion. In correspondence with the declining release rate, the serum/plasma concentration of levonorgestrel (geometric mean) declines continuously, as shown in table 5.</p><p>&nbsp;</p><p>Table 5: Total levonorgestrel concentrations in plasma:</p><table border="1" cellspacing="0" cellpadding="0" style="width:548px"><tbody><tr><td><p>Time</p></td><td><p>Total levonorgestrel concentrations in plasma (ng/l) (geometric CV%)</p></td></tr><tr><td><p>24 days after insertion</p></td><td><p>175 (37.6)</p></td></tr><tr><td><p>2 months after insertion</p></td><td><p>169 (37.1)</p></td></tr><tr><td><p>1 year after insertion</p></td><td><p>159 (37.4)</p></td></tr><tr><td><p>3 years after insertion</p></td><td><p>139 (37.8)</p></td></tr><tr><td><p>5 years after insertion</p></td><td><p>123 (38.2)</p></td></tr><tr><td><p>8 years after insertion</p></td><td><p>100 (39.9)</p></td></tr></tbody></table><p>&nbsp;</p><p>The high local drug exposure in the uterine cavity is important for the local effect of Mirena on the endometrium, and it leads to a strong concentration gradient via the endometrium to the myometrium (gradient endometrium to myometrium &gt; 100-fold) and to low concentrations of levonorgestrel in serum (gradient endometrium to serum &gt; 1,000-fold).</p><p>&nbsp;</p><p>Because of the low drug levels in plasma, the systemic effects of the progestogen are minimal.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The pharmacokinetics of levonorgestrel have been extensively studied and reported in the literature. Orally administered levonorgestrel is rapidly and completely absorbed and the absolute bioavailability is about 90%. Levonorgestrel is bound non-specifically to serum albumin and specifically to sex hormone binding globulin (SHBG). Less than 2% of the total levonorgestrel concentration in serum is present as free steroid. Levonorgestrel binds with high affinity to SHBG. Accordingly, changes in the concentration of SHBG in serum result in an increase (at higher SHBG concentrations) or in a decrease (at lower SHBG concentrations) of the total levonorgestrel concentration in serum. The concentration of SHBG declines on average by about 20% during the first two months after insertion of Mirena and remains stable thereafter, increasing only slightly by the end of the 8 years of use. The mean apparent volume of distribution of levonorgestrel is about 106 liters.</p><p>&nbsp;</p><p>Body weight and serum SHBG concentration have been shown to affect systemic levonorgestrel concentration, i.e. low body weight and/or a high SHBG level increase the levonorgestrel concentration. In women of reproductive age with low body weight (37&ndash;55&nbsp;kg) the median serum concentration of levonorgestrel is about 1.5-fold higher than normal.</p><p>&nbsp;</p><p>In postmenopausal women using Mirena together with non-oral estrogen treatment, the median serum concentration of levonorgestrel declines from 257&nbsp;pg/ml (25th to 75th percentiles: 186 to 326 pg/ml) at 12 months to 149&nbsp;pg/ml (122 to 180 pg/ml) at 60 months. When Mirena is used together with oral estrogen treatment, the serum concentration of levonorgestrel at 12 months is increased to approximately 478&nbsp;pg/ml (341 to 655 pg/ml) due to the induction of SHBG by oral estrogen treatment.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Levonorgestrel is extensively metabolized. The most important metabolic pathways are the reduction of the &Delta;4-3-oxo group and hydroxylations at positions 2&alpha;, 1&beta; and 16&beta;, followed by conjugation. In addition, CYP3A4 is involved in the oxidative metabolism of levonorgestrel. The available <em>in vitro</em> data suggest, however, that this metabolic pathway is of minor relevance compared to reduction and conjugation.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>The total clearance of levonorgestrel from plasma is approximately 1.0 ml/min/kg. Only trace amounts of levonorgestrel are excreted in unchanged form. Metabolites are excreted with feces and urine in equal amounts. The half-life, which is mainly represented by metabolites, is about one day.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>The pharmacokinetics of levonorgestrel are dependent on the concentration of SHBG which itself is influenced by estrogens and androgens. A decrease of SHBG concentration leads to a decrease of total levonorgestrel concentration in serum, indicating non-linear pharmacokinetics of levonorgestrel with regard to time. Based on the mainly local action of Mirena, no impact on the efficacy of Mirena is expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Study data revealed no special hazard for humans based on conventional studies of safety pharmacology, pharmacokinetics and toxicity, including genotoxicity, and carcinogenic potential of levonorgestrel. Levonorgestrel is a widely-used progestogen with known antiestrogenic activity. The safety profile following systemic administration is well documented. Studies in monkeys with intrauterine delivery of levonorgestrel for 9 to 12 months confirmed local pharmacological activity with good local tolerance and no signs of systemic toxicity. No embryotoxicity was seen in the rabbit following intrauterine administration of levonorgestrel.</p><p>&nbsp;</p><p>The safety evaluation of the elastomer components of the hormone reservoir, polyethylene and polypropylene materials of the product and the combination of elastomer and levonorgestrel, based on both the assessment of genetic toxicology in <em>in vitro</em> and <em>in vivo</em> test systems and biocompatibility tests in mice, rats, guinea pigs, rabbits and in vitro test systems have not revealed bioincompatibility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Hormone-elastomer core:</p></td><td style="vertical-align:top"><p>polydimethylsiloxane,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>silica</p></td></tr><tr><td style="vertical-align:top"><p>T-body:</p></td><td style="vertical-align:top"><p>polyethylene,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>barium sulphate</p></td></tr><tr><td style="vertical-align:top"><p>Removal thread:</p></td><td style="vertical-align:top"><p>polyethylene,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>iron oxide (E 172)</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The IUS is a T-shaped structure with a matrix containing the hormone around the vertical stem of the polyethylene body. The vertical stem of the IUS is inside the insertion tube and the horizontal arms are freely visible.</p><p>&nbsp;</p><p><u>Mirena intrauterine delivery system in an inserter:</u></p><p>The package contains one intrauterine delivery system and an inserter. The inserter components are the insertion tube, plunger, flange, slider and body. The product is packed into a formed blister package. The clear film is APET or PETG plastic and the white film is polyethylene.</p><p>&nbsp;</p><p><u>Mirena intrauterine delivery system in an insertion tube:</u></p><p>The package contains one intrauterine delivery system and an insertion tube. The insertion tube components are the insertion tube, flange and plunger. The product is packed into a pouch that can be ripped open. The white side of the pouch is PE plastic, and the transparent side is film made of PE/PET plastic.</p><p>&nbsp;</p><p>Not all pack types may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mirena is supplied in a sterile pack which should not be opened until required for insertion. Each product should be handled with aseptic precautions. If the seam of the package is broken, the product cannot be used.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer Oy, Pansiontie 47, 20210 Turku
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                28 October 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>